Tacrolimus

Identification

Name

Tacrolimus

Accession Number

DB00864  (APRD00276, EXPT01437)

Type

Small Molecule

Groups

Approved, Investigational

Description

Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex interacts with and inhibits calcineurin thus inhibiting both T-lymphocyte signal transduction and IL-2 transcription.

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for DB00864 (Tacrolimus)

×

Close

Synonyms

• Anhydrous tacrolimus
• Tacrolimus anhydrous
• Tacrolimus, anhydrous

External IDs

FK-506 / FK5 / K506

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Tacrolimus hydrate	WM0HAQ4WNM	109581-93-3	NWJQLQGQZSIBAF-MSLXHMNKSA-N

Product Images

PreviousNext

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Ach-tacrolimus	Capsule	1 mg	Oral	Accord Healthcare Limited	Not applicable	Not applicable
Ach-tacrolimus	Capsule	0.5 mg	Oral	Accord Healthcare Limited	Not applicable	Not applicable
Ach-tacrolimus	Capsule	5 mg	Oral	Accord Healthcare Limited	Not applicable	Not applicable
Advagraf	Capsule, extended release	3 mg	Oral	Astellas Pharma Europe Bv	2007-04-23	Not applicable
Advagraf	Capsule, extended release	3 mg	Oral	Astellas Pharma Europe Bv	2007-04-23	Not applicable
Advagraf	Capsule, extended release	5 mg	Oral	Astellas Pharma Europe Bv	2007-04-23	Not applicable
Advagraf	Capsule, extended release	1 mg	Oral	Astellas Pharma Europe Bv	2007-04-23	Not applicable
Advagraf	Capsule, extended release	5 mg	Oral	Astellas Pharma Europe Bv	2007-04-23	Not applicable
Advagraf	Capsule, extended release	3 mg	Oral	Astellas Pharma Europe Bv	2007-04-23	Not applicable
Advagraf	Capsule, extended release	0.5 mg	Oral	Astellas Pharma Inc	2008-04-09	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-tacrolimus	Capsule	1 mg	Oral	Apotex Corporation	Not applicable	Not applicable
Apo-tacrolimus	Capsule	5 mg	Oral	Apotex Corporation	Not applicable	Not applicable
Apo-tacrolimus	Capsule	0.5 mg	Oral	Apotex Corporation	Not applicable	Not applicable
Hecoria	Capsule	.5 mg/1	Oral	Novartis	2011-12-20	Not applicable
Hecoria	Capsule	1 mg/1	Oral	Novartis	2011-12-20	Not applicable
Hecoria	Capsule	5 mg/1	Oral	Novartis	2011-12-20	Not applicable
Tacrolimus	Capsule	1 mg/1	Oral	Golden State Medical Supply	2015-11-18	Not applicable
Tacrolimus	Capsule	1 mg/1	Oral	A S Medication Solutions	2011-09-30	2017-06-20
Tacrolimus	Capsule, gelatin coated	.5 mg/1	Oral	Panacea Biotec Ltd	2016-02-26	Not applicable
Tacrolimus	Capsule	5 mg/1	Oral	Sandoz	2012-01-15	Not applicable

Categories

• Antineoplastic and Immunomodulating Agents
• Calcineurin Inhibitors
• Combined Inhibitors of CYP3A4 and P-glycoprotein
• Cytochrome P-450 CYP3A Inhibitors
• Cytochrome P-450 CYP3A4 Inhibitors
• Cytochrome P-450 CYP3A4 Substrates
• Enzyme Inhibitors
• Hyperglycemia-Associated Agents
• Immunologic Factors
• Immunosuppressive Agents
• Lactones
• Macrolides
• Myelosuppressive Agents
• P-glycoprotein/ABCB1 Inducers
• P-glycoprotein/ABCB1 Inhibitors
• P-glycoprotein/ABCB1 Substrates
• Polyketides

UNII

Y5L2157C4J

CAS number

104987-11-3

Weight

Average: 804.0182
Monoisotopic: 803.481976677

Chemical Formula

C₄₄H₆₉NO₁₂

InChI Key

QJJXYPPXXYFBGM-LFZNUXCKSA-N

InChI

InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1

IUPAC Name

(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-4-azatricyclo[22.3.1.0⁴,⁹]octacos-18-ene-2,3,10,16-tetrone

SMILES

CO[[email protected]@H]1C[[email protected]@H](CC[[email protected]]1O)\C=C(/C)[[email protected]]1OC(=O)[[email protected]@H]2CCCCN2C(=O)C(=O)[[email protected]]2(O)O[[email protected]@H]([[email protected]](C[[email protected]]2C)OC)[[email protected]](C[[email protected]@H](C)C\C(C)=C\[[email protected]@H](CC=C)C(=O)C[[email protected]](O)[[email protected]]1C)OC

Pharmacology

Indication

For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.

Structured Indications

• Graft Versus Host Disease (GVHD)
• Heart Transplant Rejection
• Kidney Transplant Rejection
• Liver Transplant Rejection
• Oral Lichen Planus
• Psoriasis
• Pyoderma Gangrenosum
• Rheumatoid Arthritis
• Severe Atopic Dermatitis
• Vitiligo
• Moderate Atopic dermatitis
• Refractory Atopic dermatitis
• Refractory Rheumatoid arthritis
• Severe Rheumatoid arthritis

Pharmacodynamics

Tacrolimus is a macrolide antibiotic. It acts by reducing peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This inhibits both T-lymphocyte signal transduction and IL-2 transcription. Although this activity is similar to cyclosporine studies have shown that the incidence of acute rejection is reduced by tacrolimus use over cyclosporine. Tacrolimus has also been shown to be effective in the topical treatment of eczema, particularly atopic eczema. It suppresses inflammation in a similar way to steroids, but is not as powerful. An important dermatological advantage of tacrolimus is that it can be used directly on the face; topical steroids cannot be used on the face, as they thin the skin dramatically there. On other parts of the body, topical steroid are generally a better treatment.

Mechanism of action

The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines. Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells.

Target	Actions	Organism
APeptidyl-prolyl cis-trans isomerase FKBP1A	inhibitor	Human

Absorption

Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. The absolute bioavailability in adult kidney transplant patients is 17±10%; in adults liver transplant patients is 22±6%; in healthy subjects is 18±5%. The absolute bioavailability in pediatric liver transplant patients was 31±24%. Tacrolimus maximum blood concentrations (Cmax) and area under the curve (AUC) appeared to increase in a dose-proportional fashion in 18 fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg. When given without food, the rate and extent of absorption were the greatest. The time of the meal also affected bioavailability. When given immediately after a meal, mean Cmax was reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition. When administered 1.5 hours following the meal, mean Cmax was reduced 63%, and mean AUC was reduced 39%, relative to the fasted condition.

Volume of distribution

• 2.6 ± 2.1 L/kg [pediatric liver transplant patients]
• 1.07 ± 0.20 L/kg [patients with renal impairment, 0.02 mg/kg/4 hr dose, IV]
• 3.1 ± 1.6 L/kg [Mild Hepatic Impairment, 0.02 mg/kg/4 hr dose, IV]
• 3.7 ± 4.7 L/kg [Mild Hepatic Impairment, 7.7 mg dose, PO]
• 3.9 ± 1.0 L/kg [Severe hepatic impairment, 0.02 mg/kg/4 hr dose, IV]
• 3.1 ± 3.4 L/kg [Severe hepatic impairment, 8 mg dose, PO]

Protein binding

~99% bound to human plasma protein, primarily to albumin and alpha-1-acid glycoprotein. This is independent of concentration over a range of 5-50 ng/mL.

Metabolism

Hepatic, extensive, primarily by CYP3A4. The major metabolite identified in incubations with human liver microsomes is 13-demethyl tacrolimus. In in vitro studies, a 31-demethyl metabolite has been reported to have the same activity as tacrolimus.

Reactions:

• Tacrolimus
  31-O-Demethyltacrolimus
• Tacrolimus
  13-demethyl tacrolimus

Route of elimination

In man, less than 1% of the dose administered is excreted unchanged in urine. When administered IV, fecal elimination accounted for 92.6±30.7%, urinary elimination accounted for 2.3±1.1%.

Half life

The elimination half life in adult healthy volunteers, kidney transplant patients, liver transplants patients, and heart transplant patients are approximately 35, 19, 12, 24 hours, respectively. The elimination half life in pediatric liver transplant patients was 11.5±3.8 hours, in pediatric kidney transplant patients was 10.2±5.0 (range 3.4-25) hours.

Clearance

• 0.040 L/hr/kg [healthy subjects, IV]
• 0.172 ± 0.088 L/hr/kg [healthy subjects, oral]
• 0.083 L/hr/kg [adult kidney transplant patients, IV]
• 0.053 L/hr/kg [adult liver transplant patients, IV]
• 0.051 L/hr/kg [adult heart transplant patients, IV]
  
• 0.138 ± 0.071 L/hr/kg [pediatric liver transplant patients]
• 0.12 ± 0.04 (range 0.06-0.17) L/hr/kg [pediatric kidney transplant patients]
• 0.038 ± 0.014 L/hr/kg [patients with renal impairment, 0.02 mg/kg/4 hr dose, IV]
• 0.042 ± 0.02 L/hr/kg [Mild Hepatic Impairment, 0.02 mg/kg/4 hr dose, IV]
• 0.034 ± 0.019 L/hr/kg [Mild Hepatic Impairment, 7.7 mg dose, PO]
• 0.017 ± 0.013 L/hr/kg [Severe hepatic impairment, 0.02 mg/kg/4 hr dose, IV]
• 0.016 ± 0.011 L/hr/kg [Severe hepatic impairment, 8 mg dose, PO]

Toxicity

Side effects can be severe and include blurred vision, liver and kidney problems (it is nephrotoxic), seizures, tremors, hypertension, hypomagnesemia, diabetes mellitus, hyperkalemia, itching, insomnia, confusion. LD₅₀=134-194 mg/kg (rat).

Affected organisms

• Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Multidrug resistance protein 1	---	(T;T) / (G;T)	T Allele (G2677T)	ADR Directly Studied	The presence of this genotype in ABCB1 may indicate an increased risk of drug-induced neurotoxicity when treated with tacrolimus.	Details
Cytochrome P450 3A5	CYP3A5*1	Not Available	Functional gene	Effect Directly Studied	Patients with this genotype in CYP3A5 are extensive metabolizers and require higer doses of tacrolimus to attain the therapeutic effect.	Details

Interactions

Drug Interactions

Drug	Interaction	Drug group
1,10-Phenanthroline	The metabolism of Tacrolimus can be decreased when combined with 1,10-Phenanthroline.	Experimental
2-HYDROXY-1,4-NAPHTHOQUINONE	The metabolism of Tacrolimus can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.	Experimental
2-mercaptobenzothiazole	The metabolism of Tacrolimus can be decreased when combined with 2-mercaptobenzothiazole.	Vet Approved
2-Methoxyethanol	The risk or severity of adverse effects can be increased when Tacrolimus is combined with 2-Methoxyethanol.	Experimental
2,4-thiazolidinedione	The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Tacrolimus.	Investigational
3,4-Dichloroisocoumarin	The metabolism of Tacrolimus can be decreased when combined with 3,4-Dichloroisocoumarin.	Experimental
4-(2-Aminoethyl)Benzenesulfonyl Fluoride	The metabolism of Tacrolimus can be decreased when combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.	Experimental
Abatacept	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Abatacept.	Approved
abetimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with abetimus.	Investigational
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Tacrolimus.	Approved, Investigational
Acebutolol	The serum concentration of Acebutolol can be decreased when it is combined with Tacrolimus.	Approved
Aceclofenac	Aceclofenac may increase the nephrotoxic activities of Tacrolimus.	Approved
Acemetacin	Acemetacin may increase the nephrotoxic activities of Tacrolimus.	Approved
Acetaminophen	The serum concentration of Acetaminophen can be decreased when it is combined with Tacrolimus.	Approved
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Tacrolimus.	Withdrawn
Acetylsalicylic acid	Acetylsalicylic acid may increase the nephrotoxic activities of Tacrolimus.	Approved, Vet Approved
Acteoside	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Acteoside.	Investigational
Adalimumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Adalimumab.	Approved
Adapalene	Adapalene may increase the nephrotoxic activities of Tacrolimus.	Approved
Adefovir	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Adefovir.	Investigational
Afatinib	The serum concentration of Afatinib can be decreased when it is combined with Tacrolimus.	Approved
Afelimomab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Afelimomab.	Investigational
AICA ribonucleotide	The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Tacrolimus.	Experimental
Alaproclate	The metabolism of Tacrolimus can be decreased when combined with Alaproclate.	Experimental
Albendazole	The serum concentration of Tacrolimus can be increased when it is combined with Albendazole.	Approved, Vet Approved
Alclofenac	Alclofenac may increase the nephrotoxic activities of Tacrolimus.	Approved, Withdrawn
Aldosterone	The serum concentration of Tacrolimus can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Tacrolimus can be increased when it is combined with Alectinib.	Approved
Alefacept	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Alefacept.	Approved, Withdrawn
Alemtuzumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Alemtuzumab.	Approved, Investigational
Alfentanil	The serum concentration of Tacrolimus can be increased when it is combined with Alfentanil.	Approved, Illicit
Alicaforsen	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Alicaforsen.	Investigational
Alitretinoin	The serum concentration of Alitretinoin can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Allicin	The therapeutic efficacy of Allicin can be decreased when used in combination with Tacrolimus.	Investigational
Alminoprofen	Alminoprofen may increase the nephrotoxic activities of Tacrolimus.	Experimental
Alogliptin	The metabolism of Tacrolimus can be decreased when combined with Alogliptin.	Approved
Alpha-1-proteinase inhibitor	The metabolism of Tacrolimus can be decreased when combined with Alpha-1-proteinase inhibitor.	Approved
Altretamine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Altretamine.	Approved
Amantadine	The serum concentration of Tacrolimus can be increased when it is combined with Amantadine.	Approved
Ambrisentan	The serum concentration of Ambrisentan can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Amiloride	Amiloride may increase the hyperkalemic activities of Tacrolimus.	Approved
Aminohippuric acid	The serum concentration of Tacrolimus can be increased when it is combined with Aminohippuric acid.	Approved
Amiodarone	The metabolism of Tacrolimus can be decreased when combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be decreased when it is combined with Tacrolimus.	Approved
Amorolfine	The metabolism of Tacrolimus can be decreased when combined with Amorolfine.	Approved
Amoxapine	The metabolism of Tacrolimus can be decreased when combined with Amoxapine.	Approved
Amphotericin B	The metabolism of Tacrolimus can be decreased when combined with Amphotericin B.	Approved, Investigational
Amprenavir	The metabolism of Tacrolimus can be decreased when combined with Amprenavir.	Approved
Amsacrine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Amsacrine.	Approved
Anakinra	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Anakinra.	Approved
Andrographolide	Andrographolide may increase the nephrotoxic activities of Tacrolimus.	Investigational
Anidulafungin	The metabolism of Tacrolimus can be decreased when combined with Anidulafungin.	Approved, Investigational
Anisodamine	Anisodamine may increase the nephrotoxic activities of Tacrolimus.	Investigational
Antilymphocyte immunoglobulin (horse)	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Antilymphocyte immunoglobulin (horse).	Approved
Antipyrine	Antipyrine may increase the nephrotoxic activities of Tacrolimus.	Approved
Antithrombin III human	The metabolism of Tacrolimus can be decreased when combined with Antithrombin III human.	Approved
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Antithymocyte immunoglobulin (rabbit).	Approved
Apixaban	The metabolism of Tacrolimus can be decreased when combined with Apixaban.	Approved
Apocynin	Apocynin may increase the nephrotoxic activities of Tacrolimus.	Investigational
Apremilast	Apremilast may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Aprepitant	The serum concentration of Tacrolimus can be increased when it is combined with Aprepitant.	Approved, Investigational
Aprotinin	The metabolism of Tacrolimus can be decreased when combined with Aprotinin.	Approved, Withdrawn
Argatroban	The metabolism of Tacrolimus can be decreased when combined with Argatroban.	Approved, Investigational
Arsenic trioxide	The serum concentration of Arsenic trioxide can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Artemether	The metabolism of Tacrolimus can be decreased when combined with Artemether.	Approved
Astemizole	The serum concentration of Tacrolimus can be increased when it is combined with Astemizole.	Approved, Withdrawn
Asunaprevir	The metabolism of Tacrolimus can be decreased when combined with Asunaprevir.	Approved, Investigational
Atazanavir	The metabolism of Tacrolimus can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Atenolol can be decreased when it is combined with Tacrolimus.	Approved
Atomoxetine	The metabolism of Tacrolimus can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Atorvastatin.	Approved
Axitinib	The serum concentration of Axitinib can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Azacitidine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Azacitidine.	Approved, Investigational
Azapropazone	Azapropazone may increase the nephrotoxic activities of Tacrolimus.	Withdrawn
Azathioprine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Azathioprine.	Approved
Azelastine	Azelastine may increase the nephrotoxic activities of Tacrolimus.	Approved
Azithromycin	The serum concentration of Tacrolimus can be increased when it is combined with Azithromycin.	Approved
Bafilomycin A1	The metabolism of Tacrolimus can be decreased when combined with Bafilomycin A1.	Experimental
Balaglitazone	The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Tacrolimus.	Investigational
Balsalazide	Balsalazide may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Basiliximab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Basiliximab.	Approved, Investigational
Batimastat	The metabolism of Tacrolimus can be decreased when combined with Batimastat.	Experimental
BCG vaccine	The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Tacrolimus.	Investigational
Begelomab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Begelomab.	Experimental
Belatacept	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Belatacept.	Approved
Belimumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Belimumab.	Approved
Belinostat	The serum concentration of Belinostat can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Bempedoic acid	The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Tacrolimus.	Investigational
Benazepril	The metabolism of Tacrolimus can be decreased when combined with Benazepril.	Approved, Investigational
Bendazac	Bendazac may increase the nephrotoxic activities of Tacrolimus.	Experimental
Benorilate	Benorilate may increase the nephrotoxic activities of Tacrolimus.	Experimental
Benoxaprofen	Benoxaprofen may increase the nephrotoxic activities of Tacrolimus.	Withdrawn
Benzamidine	The metabolism of Tacrolimus can be decreased when combined with Benzamidine.	Experimental
Benznidazole	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Benznidazole.	Approved
Benzocaine	The serum concentration of Tacrolimus can be increased when it is combined with Benzocaine.	Approved
Benzoic Acid	The metabolism of Tacrolimus can be decreased when combined with Benzoic Acid.	Approved
Bepridil	The serum concentration of Tacrolimus can be increased when it is combined with Bepridil.	Approved, Withdrawn
Betamethasone	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Betamethasone.	Approved, Vet Approved
Bevonium	Bevonium may increase the nephrotoxic activities of Tacrolimus.	Experimental
Bifonazole	The metabolism of Tacrolimus can be decreased when combined with Bifonazole.	Approved
Biperiden	The serum concentration of Tacrolimus can be increased when it is combined with Biperiden.	Approved
Bivalirudin	The metabolism of Tacrolimus can be decreased when combined with Bivalirudin.	Approved, Investigational
Bleomycin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Bleomycin.	Approved
Blinatumomab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Blinatumomab.	Approved
Boceprevir	The serum concentration of Tacrolimus can be increased when it is combined with Boceprevir.	Withdrawn
Bortezomib	The metabolism of Tacrolimus can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Tacrolimus can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Tacrolimus.	Approved
Brefeldin A	The metabolism of Tacrolimus can be decreased when combined with 1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE.	Experimental
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be decreased when it is combined with Tacrolimus.	Approved
Briakinumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Briakinumab.	Investigational
Brodalumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Brodalumab.	Approved, Investigational
Bromfenac	Bromfenac may increase the nephrotoxic activities of Tacrolimus.	Approved
Bromocriptine	The serum concentration of Bromocriptine can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Bucillamine	Bucillamine may increase the nephrotoxic activities of Tacrolimus.	Investigational
Budesonide	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Budesonide.	Approved
Bufexamac	Bufexamac may increase the nephrotoxic activities of Tacrolimus.	Experimental
Buformin	The therapeutic efficacy of Buformin can be decreased when used in combination with Tacrolimus.	Withdrawn
Bumadizone	Bumadizone may increase the nephrotoxic activities of Tacrolimus.	Experimental
Buprenorphine	The serum concentration of Tacrolimus can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The serum concentration of Tacrolimus can be increased when it is combined with Buspirone.	Approved, Investigational
Busulfan	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Busulfan.	Approved, Investigational
Butenafine	The metabolism of Tacrolimus can be decreased when combined with Butenafine.	Approved
Butoconazole	The metabolism of Tacrolimus can be decreased when combined with Butoconazole.	Approved
Cabazitaxel	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cabazitaxel.	Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Tacrolimus.	Approved
Caffeine	The serum concentration of Caffeine can be decreased when it is combined with Tacrolimus.	Approved
Camostat	The metabolism of Tacrolimus can be decreased when combined with Camostat.	Experimental
Camptothecin	The serum concentration of Camptothecin can be decreased when it is combined with Tacrolimus.	Experimental
Canagliflozin	The serum concentration of Canagliflozin can be decreased when it is combined with Tacrolimus.	Approved
Canakinumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Canakinumab.	Approved, Investigational
Candesartan cilexetil	The serum concentration of Tacrolimus can be increased when it is combined with Candesartan.	Approved
Candicidin	The metabolism of Tacrolimus can be decreased when combined with Candicidin.	Withdrawn
Candoxatril	The metabolism of Tacrolimus can be decreased when combined with Candoxatril.	Experimental
Candoxatrilat	The metabolism of Tacrolimus can be decreased when combined with Candoxatrilat.	Experimental
Capecitabine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Capecitabine.	Approved, Investigational
Capric acid	The metabolism of Tacrolimus can be decreased when combined with Capric acid.	Experimental
Captopril	The metabolism of Tacrolimus can be decreased when combined with Captopril.	Approved
Carbamazepine	The metabolism of Tacrolimus can be increased when combined with Carbamazepine.	Approved, Investigational
Carbaspirin calcium	Carbaspirin calcium may increase the nephrotoxic activities of Tacrolimus.	Experimental
Carbomycin	The serum concentration of Tacrolimus can be increased when it is combined with Carbomycin.	Vet Approved
Carboplatin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Carboplatin.	Approved
Carbutamide	The therapeutic efficacy of Carbutamide can be decreased when used in combination with Tacrolimus.	Experimental
Carfilzomib	The serum concentration of Carfilzomib can be decreased when it is combined with Tacrolimus.	Approved
Carmustine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Carmustine.	Approved
Carprofen	Carprofen may increase the nephrotoxic activities of Tacrolimus.	Approved, Vet Approved, Withdrawn
Carvedilol	The serum concentration of Tacrolimus can be increased when it is combined with Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of Tacrolimus can be decreased when it is combined with Caspofungin.	Approved
Castanospermine	Castanospermine may increase the nephrotoxic activities of Tacrolimus.	Experimental
Celecoxib	Celecoxib may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Ceritinib	The serum concentration of Tacrolimus can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be decreased when it is combined with Tacrolimus.	Withdrawn
Certolizumab pegol	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Certolizumab pegol.	Approved
Cerulenin	The metabolism of Tacrolimus can be decreased when combined with Cerulenin.	Approved
Chlorambucil	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Chlorambucil.	Approved
Chloramphenicol	The serum concentration of Tacrolimus can be increased when it is combined with Chloramphenicol.	Approved, Vet Approved
Chloroquine	Chloroquine may increase the nephrotoxic activities of Tacrolimus.	Approved, Vet Approved
Chloroxine	The metabolism of Tacrolimus can be decreased when combined with Chloroxine.	Approved
Chlorpromazine	The serum concentration of Chlorpromazine can be decreased when it is combined with Tacrolimus.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Tacrolimus can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Tacrolimus can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Cholesterol	The metabolism of Tacrolimus can be decreased when combined with Cholesterol.	Experimental
Cholic Acid	The serum concentration of Tacrolimus can be decreased when it is combined with Cholic Acid.	Approved
Choline magnesium trisalicylate	Choline magnesium trisalicylate may increase the nephrotoxic activities of Tacrolimus.	Approved
Chymostatin	The metabolism of Tacrolimus can be decreased when combined with Chymostatin.	Experimental
Ciclopirox	The metabolism of Tacrolimus can be decreased when combined with Ciclopirox.	Approved, Investigational
Ciglitazone	The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Tacrolimus.	Experimental
Cilastatin	The metabolism of Tacrolimus can be decreased when combined with Cilastatin.	Approved
Cilazapril	The metabolism of Tacrolimus can be decreased when combined with Cilazapril.	Approved
Cimetidine	The serum concentration of Tacrolimus can be decreased when it is combined with Cimetidine.	Approved
Cinacalcet	The serum concentration of Tacrolimus can be decreased when it is combined with Cinacalcet.	Approved
Ciprofloxacin	The serum concentration of Ciprofloxacin can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Cisplatin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cisplatin.	Approved
Citalopram	The metabolism of Tacrolimus can be decreased when combined with Citalopram.	Approved
Cladribine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cladribine.	Approved, Investigational
Clarithromycin	The serum concentration of Tacrolimus can be increased when it is combined with Clarithromycin.	Approved
Clemastine	The metabolism of Tacrolimus can be decreased when combined with Clemastine.	Approved
Clevidipine	The serum concentration of Tacrolimus can be increased when it is combined with Clevidipine.	Approved
Clobazam	The serum concentration of Clobazam can be decreased when it is combined with Tacrolimus.	Approved, Illicit
Clofarabine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Clofarabine.	Approved, Investigational
Clofazimine	The serum concentration of Tacrolimus can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomifene	The serum concentration of Clomifene can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Clomipramine	The metabolism of Tacrolimus can be decreased when combined with Clomipramine.	Approved, Vet Approved
Clonidine	The serum concentration of Clonidine can be decreased when it is combined with Tacrolimus.	Approved
Clonixin	Clonixin may increase the nephrotoxic activities of Tacrolimus.	Approved
Clopidogrel	The serum concentration of Clopidogrel can be decreased when it is combined with Tacrolimus.	Approved, Nutraceutical
Clostridium tetani toxoid antigen (formaldehyde inactivated)	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tacrolimus.	Approved
Clotrimazole	The serum concentration of Tacrolimus can be increased when it is combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Clozapine.	Approved
Cobicistat	The metabolism of Tacrolimus can be decreased when combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be decreased when it is combined with Tacrolimus.	Approved
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Tacrolimus.	Approved
Colforsin	The serum concentration of Tacrolimus can be increased when it is combined with Colforsin.	Experimental
Conivaptan	The serum concentration of Tacrolimus can be increased when it is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated estrogens can be decreased when it is combined with Tacrolimus.	Approved
Copanlisib	The serum concentration of Copanlisib can be decreased when it is combined with Tacrolimus.	Approved
Cordycepin	The metabolism of Tacrolimus can be decreased when combined with Cordycepin.	Investigational
Corticotropin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Corticotropin.	Approved, Vet Approved
Cortisone acetate	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cortisone acetate.	Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tacrolimus.	Approved
Crizotinib	The serum concentration of Tacrolimus can be increased when it is combined with Crizotinib.	Approved
Curcumin	Curcumin may increase the nephrotoxic activities of Tacrolimus.	Investigational
Cyclophosphamide	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	Tacrolimus may increase the nephrotoxic activities of Cyclosporine.	Approved, Investigational, Vet Approved
Cytarabine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cytarabine.	Approved, Investigational
D-Limonene	D-Limonene may increase the nephrotoxic activities of Tacrolimus.	Investigational
Dabigatran etexilate	The metabolism of Tacrolimus can be decreased when combined with Dabigatran etexilate.	Approved
Dabrafenib	The serum concentration of Tacrolimus can be decreased when it is combined with Dabrafenib.	Approved
Dacarbazine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dacarbazine.	Approved, Investigational
Daclatasvir	The serum concentration of Tacrolimus can be increased when it is combined with Daclatasvir.	Approved
Daclizumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Daclizumab.	Approved, Investigational
Dactinomycin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dactinomycin.	Approved
Danazol	The serum concentration of Tacrolimus can be increased when it is combined with Danazol.	Approved
Dapagliflozin	The serum concentration of Dapagliflozin can be decreased when it is combined with Tacrolimus.	Approved
Dapoxetine	The metabolism of Tacrolimus can be decreased when combined with Dapoxetine.	Investigational
Darexaban	The metabolism of Tacrolimus can be decreased when combined with Darexaban.	Investigational
Darunavir	The metabolism of Tacrolimus can be decreased when combined with Darunavir.	Approved
Dasabuvir	The serum concentration of Tacrolimus can be increased when it is combined with Dasabuvir.	Approved
Dasatinib	The serum concentration of Tacrolimus can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Daunorubicin.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be decreased when it is combined with Tacrolimus.	Approved
Deferasirox	The serum concentration of Tacrolimus can be decreased when it is combined with Deferasirox.	Approved, Investigational
Deflazacort	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Deflazacort.	Approved
Delanzomib	The metabolism of Tacrolimus can be decreased when combined with Delanzomib.	Investigational
Delapril	The metabolism of Tacrolimus can be decreased when combined with Delapril.	Experimental
Delavirdine	The metabolism of Tacrolimus can be decreased when combined with Delavirdine.	Approved
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Tacrolimus.	Approved
Deoxyspergualin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Deoxyspergualin.	Investigational
Desipramine	The serum concentration of Tacrolimus can be increased when it is combined with Desipramine.	Approved
Desloratadine	The serum concentration of Tacrolimus can be increased when it is combined with Desloratadine.	Approved, Investigational
Dexamethasone	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexlansoprazole	The serum concentration of Tacrolimus can be increased when it is combined with Dexlansoprazole.	Approved
Dexrabeprazole	The serum concentration of Tacrolimus can be increased when it is combined with Dexrabeprazole.	Experimental
Dextromethorphan	The serum concentration of Tacrolimus can be increased when it is combined with Dextromethorphan.	Approved
Diazepam	The serum concentration of Diazepam can be decreased when it is combined with Tacrolimus.	Approved, Illicit, Vet Approved
Dichlorophene	The metabolism of Tacrolimus can be decreased when combined with Dichlorophene.	Vet Approved
Diclofenac	Diclofenac may increase the nephrotoxic activities of Tacrolimus.	Approved, Vet Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Tacrolimus.	Approved
Difenpiramide	Difenpiramide may increase the nephrotoxic activities of Tacrolimus.	Experimental
Diflunisal	Diflunisal may increase the nephrotoxic activities of Tacrolimus.	Approved
Digitoxin	The serum concentration of Digitoxin can be decreased when it is combined with Tacrolimus.	Approved
Digoxin	The serum concentration of Tacrolimus can be decreased when it is combined with Digoxin.	Approved
Dihydroergocornine	The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Tacrolimus.	Approved
Dihydroergocristine	The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Tacrolimus.	Experimental
Dihydroergocryptine	The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Tacrolimus.	Experimental
Dihydroergotamine	The metabolism of Tacrolimus can be decreased when combined with Dihydroergotamine.	Approved
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Tacrolimus.	Illicit
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dimethyl fumarate.	Approved, Investigational
Dinutuximab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dinutuximab.	Approved
Dipyridamole	The serum concentration of Dipyridamole can be decreased when it is combined with Tacrolimus.	Approved
Docetaxel	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Docetaxel.	Approved, Investigational
Domperidone	The serum concentration of Domperidone can be decreased when it is combined with Tacrolimus.	Approved, Investigational, Vet Approved
Doxazosin	The serum concentration of Tacrolimus can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Tacrolimus can be increased when it is combined with Doxepin.	Approved
Doxifluridine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Doxifluridine.	Investigational
Doxorubicin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Doxorubicin.	Approved, Investigational
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Tacrolimus.	Approved, Investigational
Doxycycline	The metabolism of Tacrolimus can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	The serum concentration of Tacrolimus can be increased when it is combined with Dronabinol.	Approved, Illicit
Dronedarone	Tacrolimus may increase the QTc-prolonging activities of Dronedarone.	Approved
Droxicam	Droxicam may increase the nephrotoxic activities of Tacrolimus.	Approved
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Tacrolimus.	Approved
Duvelisib	Duvelisib may increase the nephrotoxic activities of Tacrolimus.	Investigational
E-6201	E-6201 may increase the nephrotoxic activities of Tacrolimus.	Investigational
Ecabet	The metabolism of Tacrolimus can be decreased when combined with Ecabet.	Approved, Investigational
Econazole	The metabolism of Tacrolimus can be decreased when combined with Econazole.	Approved
Eculizumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Eculizumab.	Approved, Investigational
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Tacrolimus.	Approved
Efalizumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Efalizumab.	Approved, Investigational
Efavirenz	The serum concentration of Tacrolimus can be decreased when it is combined with Efavirenz.	Approved, Investigational
Efinaconazole	The metabolism of Tacrolimus can be decreased when combined with Efinaconazole.	Approved
Efonidipine	The serum concentration of Tacrolimus can be increased when it is combined with Efonidipine.	Approved
Elafin	The metabolism of Tacrolimus can be decreased when combined with Elafin.	Investigational
Elbasvir	The serum concentration of Elbasvir can be increased when it is combined with Tacrolimus.	Approved
Eletriptan	The serum concentration of Eletriptan can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tacrolimus.	Approved
Enalapril	The metabolism of Tacrolimus can be decreased when combined with Enalapril.	Approved, Vet Approved
Enalaprilat	The metabolism of Tacrolimus can be decreased when combined with Enalaprilat.	Approved
Enalkiren	The metabolism of Tacrolimus can be decreased when combined with Enalkiren.	Experimental
Enasidenib	The serum concentration of Enasidenib can be decreased when it is combined with Tacrolimus.	Approved
Enzalutamide	The serum concentration of Tacrolimus can be decreased when it is combined with Enzalutamide.	Approved
Epigallocatechin Gallate	The metabolism of Tacrolimus can be decreased when combined with Epigallocatechin Gallate.	Investigational
Epinastine	The serum concentration of Epinastine can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Epirizole	Epirizole may increase the nephrotoxic activities of Tacrolimus.	Approved
Epirubicin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Epirubicin.	Approved
Eplerenone	Eplerenone may increase the hyperkalemic activities of Tacrolimus.	Approved
Ergonovine	The serum concentration of Tacrolimus can be increased when it is combined with Ergonovine.	Approved
Ergotamine	The serum concentration of Tacrolimus can be increased when it is combined with Ergotamine.	Approved
Erlotinib	The serum concentration of Erlotinib can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Ertapenem	The serum concentration of Tacrolimus can be increased when it is combined with Ertapenem.	Approved, Investigational
Erythromycin	The serum concentration of Tacrolimus can be increased when it is combined with Erythromycin.	Approved, Vet Approved
Escitalopram	The metabolism of Tacrolimus can be decreased when combined with Escitalopram.	Approved, Investigational
Esomeprazole	The serum concentration of Tacrolimus can be increased when it is combined with Esomeprazole.	Approved, Investigational
Estradiol	The serum concentration of Estradiol can be decreased when it is combined with Tacrolimus.	Approved, Investigational, Vet Approved
Estramustine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Estramustine.	Approved
Estriol	The serum concentration of Estriol can be decreased when it is combined with Tacrolimus.	Approved, Vet Approved
Estrone	The serum concentration of Estrone can be decreased when it is combined with Tacrolimus.	Approved
Etanercept	Etanercept may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Ethanol	Ethanol can cause an increase in the absorption of Tacrolimus resulting in an increased serum concentration and potentially a worsening of adverse effects.	Approved
Ethenzamide	Ethenzamide may increase the nephrotoxic activities of Tacrolimus.	Experimental
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Tacrolimus.	Approved
Etodolac	Etodolac may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational, Vet Approved
Etofenamate	Etofenamate may increase the nephrotoxic activities of Tacrolimus.	Approved
Etoposide	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Etoposide.	Approved
Etoricoxib	Etoricoxib may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Etravirine	The serum concentration of Tacrolimus can be increased when it is combined with Etravirine.	Approved
Evening primrose oil	Evening primrose oil may increase the nephrotoxic activities of Tacrolimus.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Tacrolimus.	Approved
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Tacrolimus.	Approved, Investigational
exisulind	exisulind may increase the nephrotoxic activities of Tacrolimus.	Investigational
Ezetimibe	The serum concentration of Ezetimibe can be decreased when it is combined with Tacrolimus.	Approved
Faldaprevir	The metabolism of Tacrolimus can be decreased when combined with Faldaprevir.	Investigational
Felbinac	Felbinac may increase the nephrotoxic activities of Tacrolimus.	Experimental
Fenbufen	Fenbufen may increase the nephrotoxic activities of Tacrolimus.	Approved
Fenfluramine	The metabolism of Tacrolimus can be decreased when combined with Fenfluramine.	Illicit, Withdrawn
Fenofibrate	Tacrolimus may increase the nephrotoxic activities of Fenofibrate.	Approved
Fenoprofen	Fenoprofen may increase the nephrotoxic activities of Tacrolimus.	Approved
Fentanyl	The serum concentration of Tacrolimus can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fentiazac	Fentiazac may increase the nephrotoxic activities of Tacrolimus.	Experimental
Fenticonazole	The metabolism of Tacrolimus can be decreased when combined with Fenticonazole.	Experimental
Feprazone	Feprazone may increase the nephrotoxic activities of Tacrolimus.	Experimental
Ferulic acid	Ferulic acid may increase the nephrotoxic activities of Tacrolimus.	Experimental
Fesoterodine	The serum concentration of Fesoterodine can be decreased when it is combined with Tacrolimus.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be decreased when it is combined with Tacrolimus.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be decreased when it is combined with Tacrolimus.	Approved
Fingolimod	Tacrolimus may increase the immunosuppressive activities of Fingolimod.	Approved, Investigational
Floctafenine	Floctafenine may increase the nephrotoxic activities of Tacrolimus.	Approved, Withdrawn
Floxuridine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Floxuridine.	Approved
Fluconazole	The serum concentration of Tacrolimus can be increased when it is combined with Fluconazole.	Approved
Flucytosine	The metabolism of Tacrolimus can be decreased when combined with Flucytosine.	Approved
Fludarabine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Fludarabine.	Approved
Fludrocortisone	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Fludrocortisone.	Approved
Flunixin	Flunixin may increase the nephrotoxic activities of Tacrolimus.	Vet Approved
Flunoxaprofen	Flunoxaprofen may increase the nephrotoxic activities of Tacrolimus.	Experimental
Fluorouracil	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Fluorouracil.	Approved
Fluoxetine	The metabolism of Tacrolimus can be decreased when combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The serum concentration of Tacrolimus can be increased when it is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Tacrolimus can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The serum concentration of Tacrolimus can be increased when it is combined with Flurazepam.	Approved, Illicit
Flurbiprofen	Flurbiprofen may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Fluticasone furoate	The serum concentration of Fluticasone furoate can be decreased when it is combined with Tacrolimus.	Approved
Flutrimazole	The metabolism of Tacrolimus can be decreased when combined with Flutrimazole.	Experimental
Fluvastatin	The serum concentration of Fluvastatin can be increased when it is combined with Tacrolimus.	Approved
Fluvoxamine	The metabolism of Tacrolimus can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Tacrolimus can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Tacrolimus can be increased when it is combined with Fosaprepitant.	Approved
Foscarnet	Foscarnet may increase the nephrotoxic activities of Tacrolimus.	Approved
Fosinopril	The metabolism of Tacrolimus can be decreased when combined with Fosinopril.	Approved
Fosphenytoin	The serum concentration of Tacrolimus can be decreased when it is combined with Fosphenytoin.	Approved
Fusidic Acid	The serum concentration of Tacrolimus can be increased when it is combined with Fusidic Acid.	Approved
G17DT	The therapeutic efficacy of G17DT can be decreased when used in combination with Tacrolimus.	Investigational
Gabexate	The metabolism of Tacrolimus can be decreased when combined with Gabexate.	Investigational
Gallium nitrate	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Gallium nitrate.	Approved, Investigational
Gefitinib	The serum concentration of Gefitinib can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Geldanamycin	The metabolism of Tacrolimus can be decreased when combined with Geldanamycin.	Experimental
Gemcitabine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Gemcitabine.	Approved
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Gemtuzumab ozogamicin.	Approved
Genistein	The serum concentration of Tacrolimus can be increased when it is combined with Genistein.	Investigational
GI-5005	The therapeutic efficacy of GI-5005 can be decreased when used in combination with Tacrolimus.	Investigational
Glatiramer Acetate	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Glatiramer Acetate.	Approved, Investigational
Glecaprevir	The serum concentration of Glecaprevir can be decreased when it is combined with Tacrolimus.	Approved
Glibornuride	The therapeutic efficacy of Glibornuride can be decreased when used in combination with Tacrolimus.	Withdrawn
Gliclazide	The therapeutic efficacy of Gliclazide can be decreased when used in combination with Tacrolimus.	Approved
Glimepiride	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Glimepiride.	Approved
Glipizide	The therapeutic efficacy of Glipizide can be decreased when used in combination with Tacrolimus.	Approved
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Tacrolimus.	Approved
Glyburide	The serum concentration of Tacrolimus can be increased when it is combined with Glyburide.	Approved
Glycerin	The serum concentration of Tacrolimus can be increased when it is combined with Glycerin.	Approved, Investigational
Glyphosate	The metabolism of Tacrolimus can be decreased when combined with Glyphosate.	Experimental
GM6001	The metabolism of Tacrolimus can be decreased when combined with GM6001.	Experimental
Golimumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Golimumab.	Approved
Gramicidin D	The serum concentration of Tacrolimus can be increased when it is combined with Gramicidin D.	Approved
Grazoprevir	The serum concentration of Grazoprevir can be decreased when it is combined with Tacrolimus.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be decreased when it is combined with Tacrolimus.	Withdrawn
Griseofulvin	The metabolism of Tacrolimus can be decreased when combined with Griseofulvin.	Approved, Vet Approved
GS 0573	The risk or severity of adverse effects can be increased when Tacrolimus is combined with GS 0573.	Investigational
Guacetisal	Guacetisal may increase the nephrotoxic activities of Tacrolimus.	Experimental
Gusperimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Gusperimus.	Investigational
Hachimycin	The metabolism of Tacrolimus can be decreased when combined with Hachimycin.	Experimental
Haloperidol	The serum concentration of Haloperidol can be decreased when it is combined with Tacrolimus.	Approved
Haloprogin	The metabolism of Tacrolimus can be decreased when combined with Haloprogin.	Approved, Withdrawn
Hexetidine	The metabolism of Tacrolimus can be decreased when combined with Hexetidine.	Approved
Higenamine	Higenamine may increase the nephrotoxic activities of Tacrolimus.	Investigational
Human C1-esterase inhibitor	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Human C1-esterase inhibitor.	Approved
Hydrocortisone	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Hydrocortisone.	Approved, Vet Approved
Hydroxyurea	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Hydroxyurea.	Approved
Hypericin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Hypericin.	Investigational
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ibritumomab tiuxetan.	Approved
Ibrutinib	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ibrutinib.	Approved
Ibuprofen	Ibuprofen may increase the nephrotoxic activities of Tacrolimus.	Approved
Ibuproxam	Ibuproxam may increase the nephrotoxic activities of Tacrolimus.	Withdrawn
Icatibant	Icatibant may increase the nephrotoxic activities of Tacrolimus.	Approved
Idarubicin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Idarubicin.	Approved
Idelalisib	The serum concentration of Tacrolimus can be increased when it is combined with Idelalisib.	Approved
Idraparinux	The metabolism of Tacrolimus can be decreased when combined with Idraparinux.	Investigational
Ifosfamide	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ifosfamide.	Approved
Imatinib	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Imatinib.	Approved
Imidapril	The metabolism of Tacrolimus can be decreased when combined with Imidapril.	Investigational
Imidazole salicylate	Imidazole salicylate may increase the nephrotoxic activities of Tacrolimus.	Experimental
Imipramine	The serum concentration of Imipramine can be decreased when it is combined with Tacrolimus.	Approved
Imiquimod	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Imiquimod.	Approved, Investigational
Indacaterol	The serum concentration of Indacaterol can be decreased when it is combined with Tacrolimus.	Approved
Indalpine	The metabolism of Tacrolimus can be decreased when combined with Indalpine.	Investigational, Withdrawn
Indinavir	The metabolism of Tacrolimus can be decreased when combined with Indinavir.	Approved
Indobufen	Indobufen may increase the nephrotoxic activities of Tacrolimus.	Investigational
Indomethacin	Indomethacin may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Indoprofen	Indoprofen may increase the nephrotoxic activities of Tacrolimus.	Withdrawn
Infliximab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Infliximab.	Approved
INGN 201	The therapeutic efficacy of INGN 201 can be decreased when used in combination with Tacrolimus.	Investigational
INGN 225	The therapeutic efficacy of INGN 225 can be decreased when used in combination with Tacrolimus.	Investigational
Inotuzumab ozogamicin	The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Tacrolimus.	Approved
Insulin Aspart	The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Tacrolimus.	Approved
Insulin Detemir	The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Tacrolimus.	Approved
Insulin Glargine	The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Tacrolimus.	Approved
Insulin Glulisine	The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Tacrolimus.	Approved
Insulin Human	The therapeutic efficacy of Insulin Human can be decreased when used in combination with Tacrolimus.	Approved, Investigational
Insulin Lispro	The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Tacrolimus.	Approved
Insulin Pork	The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Tacrolimus.	Approved
Irinotecan	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Irinotecan.	Approved, Investigational
Isavuconazonium	The metabolism of Tacrolimus can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isoconazole	The metabolism of Tacrolimus can be decreased when combined with Isoconazole.	Approved
Isoflurophate	The metabolism of Tacrolimus can be decreased when combined with Isoflurophate.	Approved, Withdrawn
Isoxicam	Isoxicam may increase the nephrotoxic activities of Tacrolimus.	Withdrawn
Isradipine	The serum concentration of Tacrolimus can be increased when it is combined with Isradipine.	Approved
Itraconazole	The serum concentration of Tacrolimus can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Tacrolimus can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Ivermectin can be decreased when it is combined with Tacrolimus.	Approved, Vet Approved
Ixazomib	The metabolism of Tacrolimus can be decreased when combined with Ixazomib.	Approved
Josamycin	The serum concentration of Tacrolimus can be increased when it is combined with Josamycin.	Approved
Kebuzone	Kebuzone may increase the nephrotoxic activities of Tacrolimus.	Experimental
Ketamine	The serum concentration of Tacrolimus can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketazolam	The serum concentration of Ketazolam can be decreased when it is combined with Tacrolimus.	Approved
Ketoconazole	The serum concentration of Tacrolimus can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoprofen	Ketoprofen may increase the nephrotoxic activities of Tacrolimus.	Approved, Vet Approved
Ketorolac	Ketorolac may increase the nephrotoxic activities of Tacrolimus.	Approved
Kitasamycin	The serum concentration of Tacrolimus can be increased when it is combined with Kitasamycin.	Experimental
L-Phenylalanine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with L-Phenylalanine.	Approved, Nutraceutical
Lamivudine	The serum concentration of Lamivudine can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Lansoprazole	The serum concentration of Tacrolimus can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of Tacrolimus can be increased when it is combined with Lapatinib.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Tacrolimus.	Approved
Leflunomide	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Leflunomide.	Approved, Investigational
Lenalidomide	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Lenalidomide.	Approved
Lenvatinib	The serum concentration of Lenvatinib can be decreased when it is combined with Tacrolimus.	Approved
Lepirudin	The metabolism of Tacrolimus can be decreased when combined with Lepirudin.	Approved
Letaxaban	The metabolism of Tacrolimus can be decreased when combined with Letaxaban.	Investigational
Levetiracetam	The serum concentration of Levetiracetam can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Levofloxacin	Levofloxacin may increase the QTc-prolonging activities of Tacrolimus.	Approved, Investigational
Levomilnacipran	The metabolism of Tacrolimus can be decreased when combined with Levomilnacipran.	Approved
Levothyroxine	The serum concentration of Tacrolimus can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of Tacrolimus can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Linagliptin	The serum concentration of Linagliptin can be decreased when it is combined with Tacrolimus.	Approved
Liothyronine	The serum concentration of Tacrolimus can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Tacrolimus can be decreased when it is combined with Liotrix.	Approved
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Tacrolimus.	Approved
Lisinopril	The metabolism of Tacrolimus can be decreased when combined with Lisinopril.	Approved, Investigational
Lisofylline	Lisofylline may increase the nephrotoxic activities of Tacrolimus.	Investigational
Lisuride	The risk or severity of adverse effects can be increased when Lisuride is combined with Tacrolimus.	Approved
Lomitapide	The serum concentration of Tacrolimus can be increased when it is combined with Lomitapide.	Approved
Lomustine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Lomustine.	Approved
Lonazolac	Lonazolac may increase the nephrotoxic activities of Tacrolimus.	Experimental
Loperamide	The serum concentration of Loperamide can be decreased when it is combined with Tacrolimus.	Approved
Lopinavir	The metabolism of Tacrolimus can be decreased when combined with Lopinavir.	Approved
Loratadine	The serum concentration of Tacrolimus can be increased when it is combined with Loratadine.	Approved
Lornoxicam	Lornoxicam may increase the nephrotoxic activities of Tacrolimus.	Approved
Losartan	The serum concentration of Losartan can be decreased when it is combined with Tacrolimus.	Approved
Lovastatin	The metabolism of Tacrolimus can be decreased when combined with Lovastatin.	Approved, Investigational
Loxoprofen	Loxoprofen may increase the nephrotoxic activities of Tacrolimus.	Approved
Luliconazole	The serum concentration of Tacrolimus can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Tacrolimus can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	Lumiracoxib may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Lysergic Acid Diethylamide	The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Tacrolimus.	Illicit, Withdrawn
Magnesium salicylate	Magnesium salicylate may increase the nephrotoxic activities of Tacrolimus.	Approved
Mannitol	The serum concentration of Mannitol can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Maprotiline	The serum concentration of Tacrolimus can be increased when it is combined with Maprotiline.	Approved
Masoprocol	Masoprocol may increase the nephrotoxic activities of Tacrolimus.	Approved
Mebendazole	The serum concentration of Tacrolimus can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Mechlorethamine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mechlorethamine.	Approved
Meclofenamic acid	Meclofenamic acid may increase the nephrotoxic activities of Tacrolimus.	Approved, Vet Approved
Mefenamic acid	Mefenamic acid may increase the nephrotoxic activities of Tacrolimus.	Approved
Mefloquine	The serum concentration of Tacrolimus can be increased when it is combined with Mefloquine.	Approved
Megestrol acetate	The serum concentration of Tacrolimus can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Melagatran	The metabolism of Tacrolimus can be decreased when combined with Melagatran.	Experimental
Meloxicam	Meloxicam may increase the nephrotoxic activities of Tacrolimus.	Approved, Vet Approved
Melphalan	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Melphalan.	Approved
Mepartricin	The metabolism of Tacrolimus can be decreased when combined with Mepartricin.	Experimental
Mepolizumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mepolizumab.	Approved, Investigational
Meprobamate	The serum concentration of Tacrolimus can be increased when it is combined with Meprobamate.	Approved, Illicit
Mercaptopurine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mercaptopurine.	Approved
Mesalazine	Mesalazine may increase the nephrotoxic activities of Tacrolimus.	Approved
Metamizole	Metamizole may increase the nephrotoxic activities of Tacrolimus.	Withdrawn
Metergoline	The risk or severity of adverse effects can be increased when Metergoline is combined with Tacrolimus.	Experimental
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus.	Approved
Methadone	The serum concentration of Tacrolimus can be increased when it is combined with Methadone.	Approved
Methotrexate	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Methotrexate.	Approved
Methylergometrine	The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tacrolimus.	Approved
Methylprednisolone	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Methylprednisolone.	Approved, Vet Approved
Methysergide	The risk or severity of adverse effects can be increased when Methysergide is combined with Tacrolimus.	Approved
Metoprolol	The serum concentration of Metoprolol can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Mevastatin	The metabolism of Tacrolimus can be decreased when combined with Mevastatin.	Experimental
Mibefradil	The serum concentration of Tacrolimus can be increased when it is combined with Mibefradil.	Withdrawn
Micafungin	The metabolism of Tacrolimus can be decreased when combined with Micafungin.	Approved, Investigational
Miconazole	The metabolism of Tacrolimus can be decreased when combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Midazolam can be decreased when it is combined with Tacrolimus.	Approved, Illicit
Mifepristone	Mifepristone may increase the QTc-prolonging activities of Tacrolimus.	Approved, Investigational
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Tacrolimus.	Approved
Miglustat	The therapeutic efficacy of Miglustat can be decreased when used in combination with Tacrolimus.	Approved
Milnacipran	The metabolism of Tacrolimus can be decreased when combined with Milnacipran.	Approved
Miltefosine	The metabolism of Tacrolimus can be decreased when combined with Miltefosine.	Approved
Mirabegron	The serum concentration of Mirabegron can be decreased when it is combined with Tacrolimus.	Approved
Mitiglinide	The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Tacrolimus.	Approved, Investigational
Mitomycin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mitomycin.	Approved
Mitotane	The serum concentration of Tacrolimus can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mitoxantrone.	Approved, Investigational
Mizoribine	Mizoribine may increase the nephrotoxic activities of Tacrolimus.	Investigational
Moexipril	The metabolism of Tacrolimus can be decreased when combined with Moexipril.	Approved
Mofebutazone	Mofebutazone may increase the nephrotoxic activities of Tacrolimus.	Experimental
Monensin	The metabolism of Tacrolimus can be decreased when combined with Monensin.	Vet Approved
Morphine	The serum concentration of Morphine can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Muromonab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Muromonab.	Approved, Investigational
Mycophenolate mofetil	Mycophenolate mofetil may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Mycophenolic acid	Mycophenolic acid may increase the nephrotoxic activities of Tacrolimus.	Approved
Myxothiazol	The metabolism of Tacrolimus can be decreased when combined with Myxothiazol.	Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline	The metabolism of Tacrolimus can be decreased when combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.	Experimental
Nabumetone	Nabumetone may increase the nephrotoxic activities of Tacrolimus.	Approved
Nadolol	The serum concentration of Nadolol can be decreased when it is combined with Tacrolimus.	Approved
Nafamostat	The metabolism of Tacrolimus can be decreased when combined with Nafamostat.	Approved, Investigational
Naftifine	The metabolism of Tacrolimus can be decreased when combined with Naftifine.	Approved
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Tacrolimus.	Approved
Naloxone	The serum concentration of Naloxone can be decreased when it is combined with Tacrolimus.	Approved, Vet Approved
Naltrexone	The serum concentration of Tacrolimus can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naproxen	Naproxen may increase the nephrotoxic activities of Tacrolimus.	Approved, Vet Approved
Naringenin	The serum concentration of Tacrolimus can be increased when it is combined with Naringenin.	Experimental
Natalizumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Natalizumab.	Approved, Investigational
Natamycin	The metabolism of Tacrolimus can be decreased when combined with Natamycin.	Approved
Nateglinide	The therapeutic efficacy of Nateglinide can be decreased when used in combination with Tacrolimus.	Approved, Investigational
Nefazodone	The metabolism of Tacrolimus can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelarabine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Nelarabine.	Approved, Investigational
Nelfinavir	The metabolism of Tacrolimus can be decreased when combined with Nelfinavir.	Approved
Neostigmine	The serum concentration of Tacrolimus can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Nepafenac	Nepafenac may increase the nephrotoxic activities of Tacrolimus.	Approved
Netupitant	The serum concentration of Tacrolimus can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Tacrolimus can be increased when combined with Nevirapine.	Approved
Nicardipine	The serum concentration of Tacrolimus can be increased when it is combined with Nicardipine.	Approved
Nicergoline	The risk or severity of adverse effects can be increased when Nicergoline is combined with Tacrolimus.	Approved
Nifedipine	The serum concentration of Tacrolimus can be increased when it is combined with Nifedipine.	Approved
Nifenazone	Nifenazone may increase the nephrotoxic activities of Tacrolimus.	Experimental
Niflumic Acid	Niflumic Acid may increase the nephrotoxic activities of Tacrolimus.	Approved
Nifuratel	The metabolism of Tacrolimus can be decreased when combined with Nifuratel.	Experimental
Nikkomycin Z	The metabolism of Tacrolimus can be decreased when combined with Nikkomycin Z.	Investigational
Nilotinib	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Nilotinib.	Approved, Investigational
Nimesulide	Nimesulide may increase the nephrotoxic activities of Tacrolimus.	Approved, Withdrawn
Nimodipine	The serum concentration of Tacrolimus can be increased when it is combined with Nimodipine.	Approved
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Tacrolimus.	Approved
Nitrazepam	The serum concentration of Tacrolimus can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Tacrolimus can be increased when it is combined with Nitrendipine.	Approved
Nitroaspirin	The metabolism of Tacrolimus can be decreased when combined with Nitroaspirin.	Investigational
Nitroxoline	The metabolism of Tacrolimus can be decreased when combined with Nitroxoline.	Approved
Nizatidine	The serum concentration of Nizatidine can be decreased when it is combined with Tacrolimus.	Approved
Norethisterone	The serum concentration of Tacrolimus can be decreased when it is combined with Norethisterone.	Approved
Nystatin	The metabolism of Tacrolimus can be decreased when combined with Nystatin.	Approved, Vet Approved
Obinutuzumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Obinutuzumab.	Approved
Odanacatib	The serum concentration of Odanacatib can be decreased when it is combined with Tacrolimus.	Investigational
Olanzapine	The metabolism of Tacrolimus can be decreased when combined with Olanzapine.	Approved, Investigational
Olaparib	The metabolism of Tacrolimus can be decreased when combined with Olaparib.	Approved
Oleandomycin	The serum concentration of Tacrolimus can be increased when it is combined with Oleandomycin.	Vet Approved
Olopatadine	Olopatadine may increase the nephrotoxic activities of Tacrolimus.	Approved
Olsalazine	Olsalazine may increase the nephrotoxic activities of Tacrolimus.	Approved
Omapatrilat	The metabolism of Tacrolimus can be decreased when combined with Omapatrilat.	Investigational
Ombitasvir	The serum concentration of Tacrolimus can be increased when it is combined with Ombitasvir.	Approved
Omeprazole	The serum concentration of Tacrolimus can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Omoconazole	The metabolism of Tacrolimus can be decreased when combined with Omoconazole.	Experimental
Orgotein	Orgotein may increase the nephrotoxic activities of Tacrolimus.	Vet Approved
Osimertinib	The serum concentration of Tacrolimus can be increased when it is combined with Osimertinib.	Approved
Otamixaban	The metabolism of Tacrolimus can be decreased when combined with Otamixaban.	Investigational
Oxaliplatin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Oxaliplatin.	Approved, Investigational
Oxaprozin	Oxaprozin may increase the nephrotoxic activities of Tacrolimus.	Approved
Oxiconazole	The metabolism of Tacrolimus can be decreased when combined with Oxiconazole.	Approved
Oxyphenbutazone	Oxyphenbutazone may increase the nephrotoxic activities of Tacrolimus.	Withdrawn
P-Nitrophenol	The serum concentration of Tacrolimus can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Paclitaxel.	Approved, Vet Approved
pafuramidine	The metabolism of Tacrolimus can be decreased when combined with pafuramidine.	Investigational
Palbociclib	The serum concentration of Tacrolimus can be increased when it is combined with Palbociclib.	Approved
Palmitic Acid	The serum concentration of Tacrolimus can be increased when it is combined with Palmitic Acid.	Experimental
Panobinostat	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Panobinostat.	Approved, Investigational
Pantoprazole	The serum concentration of Tacrolimus can be increased when it is combined with Pantoprazole.	Approved
Paquinimod	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Paquinimod.	Investigational
Parecoxib	Parecoxib may increase the nephrotoxic activities of Tacrolimus.	Approved
Paritaprevir	The serum concentration of Tacrolimus can be increased when it is combined with Paritaprevir.	Approved
Paroxetine	The metabolism of Tacrolimus can be decreased when combined with Paroxetine.	Approved, Investigational
Parthenolide	Parthenolide may increase the nephrotoxic activities of Tacrolimus.	Investigational
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Tacrolimus.	Approved
Pegaspargase	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pegaspargase.	Approved, Investigational
Pemetrexed	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pemetrexed.	Approved, Investigational
Pentamidine	The metabolism of Tacrolimus can be decreased when combined with Pentamidine.	Approved
Pentobarbital	The metabolism of Tacrolimus can be increased when combined with Pentobarbital.	Approved, Vet Approved
Pentostatin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pentostatin.	Approved, Investigational
Pergolide	The risk or severity of adverse effects can be increased when Pergolide is combined with Tacrolimus.	Approved, Vet Approved, Withdrawn
Perindopril	The metabolism of Tacrolimus can be decreased when combined with Perindopril.	Approved
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Tacrolimus.	Approved, Withdrawn
Phenobarbital	The metabolism of Tacrolimus can be increased when combined with Phenobarbital.	Approved
Phenylbutazone	Phenylbutazone may increase the nephrotoxic activities of Tacrolimus.	Approved, Vet Approved
Phenytoin	The serum concentration of Tacrolimus can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Phosphoramidon	The metabolism of Tacrolimus can be decreased when combined with Phosphoramidon.	Experimental
Pibrentasvir	The serum concentration of Pibrentasvir can be decreased when it is combined with Tacrolimus.	Approved
Pimecrolimus	Pimecrolimus may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Pimozide	The serum concentration of Tacrolimus can be increased when it is combined with Pimozide.	Approved
Pioglitazone	The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Tacrolimus.	Approved, Investigational
Pirarubicin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pirarubicin.	Investigational
Pirfenidone	Pirfenidone may increase the nephrotoxic activities of Tacrolimus.	Investigational
Piroxicam	Piroxicam may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Pirprofen	Pirprofen may increase the nephrotoxic activities of Tacrolimus.	Experimental
Pitavastatin	The serum concentration of Pitavastatin can be decreased when it is combined with Tacrolimus.	Approved
Platelet Activating Factor	The serum concentration of Tacrolimus can be decreased when it is combined with Platelet Activating Factor.	Experimental
Pomalidomide	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pomalidomide.	Approved
Ponatinib	The serum concentration of Ponatinib can be decreased when it is combined with Tacrolimus.	Approved
Posaconazole	The serum concentration of Tacrolimus can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Pralatrexate	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pralatrexate.	Approved
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Tacrolimus.	Approved, Investigational
Pranoprofen	Pranoprofen may increase the nephrotoxic activities of Tacrolimus.	Experimental
Pravastatin	The serum concentration of Pravastatin can be decreased when it is combined with Tacrolimus.	Approved
Prazosin	The serum concentration of Prazosin can be decreased when it is combined with Tacrolimus.	Approved
Prednisolone	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Prednisolone.	Approved, Vet Approved
Prednisone	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Prednisone.	Approved, Vet Approved
Primidone	The metabolism of Tacrolimus can be increased when combined with Primidone.	Approved, Vet Approved
Prinomastat	The metabolism of Tacrolimus can be decreased when combined with Prinomastat.	Investigational
Probenecid	The serum concentration of Tacrolimus can be increased when it is combined with Probenecid.	Approved
Procarbazine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Procarbazine.	Approved
Progesterone	The serum concentration of Tacrolimus can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Proglumetacin	Proglumetacin may increase the nephrotoxic activities of Tacrolimus.	Experimental
Promethazine	The serum concentration of Tacrolimus can be increased when it is combined with Promethazine.	Approved
Propacetamol	Propacetamol may increase the nephrotoxic activities of Tacrolimus.	Approved
Propafenone	The serum concentration of Tacrolimus can be increased when it is combined with Propafenone.	Approved
Propranolol	The serum concentration of Propranolol can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Propyphenazone	Propyphenazone may increase the nephrotoxic activities of Tacrolimus.	Experimental
Proquazone	Proquazone may increase the nephrotoxic activities of Tacrolimus.	Experimental
Protriptyline	The serum concentration of Tacrolimus can be increased when it is combined with Protriptyline.	Approved
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Tacrolimus.	Approved
PTC299	PTC299 may increase the nephrotoxic activities of Tacrolimus.	Investigational
Pyrrolnitrin	The metabolism of Tacrolimus can be decreased when combined with Pyrrolnitrin.	Experimental
Quercetin	The serum concentration of Tacrolimus can be increased when it is combined with Quercetin.	Experimental
Quetiapine	The serum concentration of Quetiapine can be decreased when it is combined with Tacrolimus.	Approved
Quinacrine	The serum concentration of Tacrolimus can be increased when it is combined with Quinacrine.	Approved
Quinapril	The metabolism of Tacrolimus can be decreased when combined with Quinapril.	Approved, Investigational
Quinidine	The serum concentration of Quinidine can be decreased when it is combined with Tacrolimus.	Approved
Quinine	The serum concentration of Quinine can be decreased when it is combined with Tacrolimus.	Approved
Rabeprazole	The serum concentration of Tacrolimus can be increased when it is combined with Rabeprazole.	Approved, Investigational
Rabies virus inactivated antigen, A	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Rabies virus inactivated antigen, A.	Approved
Rabies virus inactivated antigen, A	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tacrolimus.	Approved
Racecadotril	The metabolism of Tacrolimus can be decreased when combined with Racecadotril.	Investigational
Radicicol	The metabolism of Tacrolimus can be decreased when combined with Radicicol.	Experimental
Ramipril	The metabolism of Tacrolimus can be decreased when combined with Ramipril.	Approved
Ranitidine	The serum concentration of Ranitidine can be decreased when it is combined with Tacrolimus.	Approved
Reboxetine	The serum concentration of Tacrolimus can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Tacrolimus can be increased when it is combined with Regorafenib.	Approved
Remikiren	The metabolism of Tacrolimus can be decreased when combined with Remikiren.	Approved
Repaglinide	The therapeutic efficacy of Repaglinide can be decreased when used in combination with Tacrolimus.	Approved, Investigational
Reserpine	The serum concentration of Tacrolimus can be decreased when it is combined with Reserpine.	Approved
Resveratrol	Resveratrol may increase the nephrotoxic activities of Tacrolimus.	Experimental, Investigational
Rifabutin	The serum concentration of Tacrolimus can be decreased when it is combined with Rifabutin.	Approved
Rifampicin	The serum concentration of Tacrolimus can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Tacrolimus can be decreased when it is combined with Rifapentine.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Tacrolimus.	Approved, Investigational
Rilonacept	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Rilonacept.	Approved
Rilpivirine	The serum concentration of Tacrolimus can be increased when it is combined with Rilpivirine.	Approved
Rindopepimut	The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tacrolimus.	Investigational
Risperidone	The serum concentration of Risperidone can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Ritonavir	The serum concentration of Tacrolimus can be increased when it is combined with Ritonavir.	Approved, Investigational
Rituximab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Rituximab.	Approved
Rivaroxaban	The metabolism of Tacrolimus can be decreased when combined with Rivaroxaban.	Approved
Rofecoxib	Rofecoxib may increase the nephrotoxic activities of Tacrolimus.	Investigational, Withdrawn
Roflumilast	Roflumilast may increase the immunosuppressive activities of Tacrolimus.	Approved
Rolapitant	The serum concentration of Tacrolimus can be increased when it is combined with Rolapitant.	Approved
Romidepsin	The serum concentration of Romidepsin can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Rosiglitazone	The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Tacrolimus.	Approved, Investigational
Rosuvastatin	The serum concentration of Rosuvastatin can be increased when it is combined with Tacrolimus.	Approved
Rotavirus Vaccine	The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Tacrolimus.	Approved
Rubella virus vaccine	The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Tacrolimus.	Approved
Ruxolitinib	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ruxolitinib.	Approved
S-3304	The metabolism of Tacrolimus can be decreased when combined with S-3304.	Investigational
Salicylamide	Salicylamide may increase the nephrotoxic activities of Tacrolimus.	Approved
Salicylhydroxamic Acid	The metabolism of Tacrolimus can be decreased when combined with Salicylhydroxamic Acid.	Experimental
Salicylic acid	The metabolism of Tacrolimus can be decreased when combined with Salicylic acid.	Approved, Vet Approved
Salsalate	Salsalate may increase the nephrotoxic activities of Tacrolimus.	Approved
Saquinavir	The metabolism of Tacrolimus can be decreased when combined with Saquinavir.	Approved, Investigational
Saxagliptin	The metabolism of Tacrolimus can be decreased when combined with Saxagliptin.	Approved
Scopolamine	The serum concentration of Tacrolimus can be increased when it is combined with Scopolamine.	Approved
Secukinumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Secukinumab.	Approved
Selegiline	The serum concentration of Tacrolimus can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be decreased when it is combined with Tacrolimus.	Approved
Semapimod	Semapimod may increase the nephrotoxic activities of Tacrolimus.	Investigational
Seocalcitol	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Seocalcitol.	Experimental
Seratrodast	Seratrodast may increase the nephrotoxic activities of Tacrolimus.	Approved
Serrapeptase	Serrapeptase may increase the nephrotoxic activities of Tacrolimus.	Investigational
Sertaconazole	The metabolism of Tacrolimus can be decreased when combined with Sertaconazole.	Approved
Sertraline	The metabolism of Tacrolimus can be decreased when combined with Sertraline.	Approved
Sevelamer	The serum concentration of Tacrolimus can be decreased when it is combined with Sevelamer.	Approved
Sildenafil	The metabolism of Tacrolimus can be decreased when combined with Sildenafil.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Tacrolimus.	Approved
Siltuximab	The serum concentration of Tacrolimus can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The metabolism of Tacrolimus can be decreased when combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Tacrolimus can be increased when it is combined with Simvastatin.	Approved
Sinefungin	The metabolism of Tacrolimus can be decreased when combined with Sinefungin.	Experimental
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tacrolimus.	Approved
Sirolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sirolimus.	Approved, Investigational
Sitagliptin	The metabolism of Tacrolimus can be decreased when combined with Sitagliptin.	Approved, Investigational
Sivelestat	The metabolism of Tacrolimus can be decreased when combined with Sivelestat.	Investigational
Sofosbuvir	The serum concentration of Sofosbuvir can be decreased when it is combined with Tacrolimus.	Approved
Solithromycin	The serum concentration of Tacrolimus can be increased when it is combined with Solithromycin.	Investigational
Sorafenib	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sorafenib.	Approved, Investigational
Sotagliflozin	The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Tacrolimus.	Investigational
Sparfloxacin	The serum concentration of Sparfloxacin can be decreased when it is combined with Tacrolimus.	Approved
Sphingosine	The serum concentration of Sphingosine can be decreased when it is combined with Tacrolimus.	Experimental
Spirapril	The metabolism of Tacrolimus can be decreased when combined with Spirapril.	Approved
Spironolactone	Spironolactone may increase the hyperkalemic activities of Tacrolimus.	Approved
SRP 299	The therapeutic efficacy of SRP 299 can be decreased when used in combination with Tacrolimus.	Investigational
SRT501	SRT501 may increase the nephrotoxic activities of Tacrolimus.	Investigational
Staurosporine	The serum concentration of Tacrolimus can be increased when it is combined with Staurosporine.	Experimental
Stepronin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Stepronin.	Approved
Stiripentol	The serum concentration of Tacrolimus can be increased when it is combined with Stiripentol.	Approved
Streptozocin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Streptozocin.	Approved
Sulconazole	The metabolism of Tacrolimus can be decreased when combined with Sulconazole.	Approved
Sulfasalazine	Sulfasalazine may increase the nephrotoxic activities of Tacrolimus.	Approved
Sulfinpyrazone	The serum concentration of Tacrolimus can be increased when it is combined with Sulfinpyrazone.	Approved
Sulfisoxazole	The metabolism of Tacrolimus can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulindac	Sulindac may increase the nephrotoxic activities of Tacrolimus.	Approved
Sulodexide	The therapeutic efficacy of Sulodexide can be decreased when used in combination with Tacrolimus.	Approved, Investigational
Sumatriptan	The serum concentration of Tacrolimus can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sunitinib.	Approved, Investigational
Suprofen	Suprofen may increase the nephrotoxic activities of Tacrolimus.	Approved, Withdrawn
Suxibuzone	Suxibuzone may increase the nephrotoxic activities of Tacrolimus.	Experimental
Tacrine	The serum concentration of Tacrolimus can be increased when it is combined with Tacrine.	Withdrawn
Tamoxifen	The serum concentration of Tamoxifen can be decreased when it is combined with Tacrolimus.	Approved
Tarenflurbil	Tarenflurbil may increase the nephrotoxic activities of Tacrolimus.	Investigational
Taurocholic Acid	The serum concentration of Taurocholic Acid can be decreased when it is combined with Tacrolimus.	Experimental
Tavaborole	The metabolism of Tacrolimus can be decreased when combined with Tavaborole.	Approved
Tecemotide	The therapeutic efficacy of Tecemotide can be decreased when used in combination with Tacrolimus.	Investigational
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Tacrolimus.	Approved
Telaprevir	The serum concentration of Tacrolimus can be increased when it is combined with Telaprevir.	Withdrawn
Telithromycin	The serum concentration of Tacrolimus can be increased when it is combined with Telithromycin.	Approved
Telmisartan	The serum concentration of Tacrolimus can be increased when it is combined with Telmisartan.	Approved, Investigational
Temocapril	The metabolism of Tacrolimus can be decreased when combined with Temocapril.	Experimental, Investigational
Temozolomide	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Temozolomide.	Approved, Investigational
Temsirolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Temsirolimus.	Approved
Tenidap	Tenidap may increase the nephrotoxic activities of Tacrolimus.	Experimental
Teniposide	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Teniposide.	Approved
Tenoxicam	Tenoxicam may increase the nephrotoxic activities of Tacrolimus.	Approved
Tepoxalin	Tepoxalin may increase the nephrotoxic activities of Tacrolimus.	Vet Approved
Terazosin	The serum concentration of Tacrolimus can be increased when it is combined with Terazosin.	Approved
Terbinafine	The metabolism of Tacrolimus can be decreased when combined with Terbinafine.	Approved, Investigational, Vet Approved
Terconazole	The metabolism of Tacrolimus can be decreased when combined with Terconazole.	Approved
Terfenadine	The serum concentration of Tacrolimus can be increased when it is combined with Terfenadine.	Withdrawn
Terguride	The risk or severity of adverse effects can be increased when Terguride is combined with Tacrolimus.	Experimental
Teriflunomide	Teriflunomide may increase the nephrotoxic activities of Tacrolimus.	Approved
Tesmilifene	The serum concentration of Tacrolimus can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Tacrolimus can be increased when it is combined with Testosterone.	Approved, Investigational
TG4010	The therapeutic efficacy of TG4010 can be decreased when used in combination with Tacrolimus.	Investigational
Thalidomide	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Thalidomide.	Approved, Investigational, Withdrawn
Thiorphan	The metabolism of Tacrolimus can be decreased when combined with Thiorphan.	Experimental
Thiotepa	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Thiotepa.	Approved
Thymol	The metabolism of Tacrolimus can be decreased when combined with Thymol.	Approved
Tiaprofenic acid	Tiaprofenic acid may increase the nephrotoxic activities of Tacrolimus.	Approved
Ticagrelor	The serum concentration of Ticagrelor can be decreased when it is combined with Tacrolimus.	Approved
Ticlopidine	The metabolism of Tacrolimus can be decreased when combined with Ticlopidine.	Approved
Timolol	The serum concentration of Timolol can be decreased when it is combined with Tacrolimus.	Approved
Tinoridine	Tinoridine may increase the nephrotoxic activities of Tacrolimus.	Investigational
Tioconazole	The metabolism of Tacrolimus can be decreased when combined with Tioconazole.	Approved
Tioguanine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Tioguanine.	Approved
Tipranavir	The metabolism of Tacrolimus can be decreased when combined with Tipranavir.	Approved, Investigational
Tocilizumab	The serum concentration of Tacrolimus can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	Tacrolimus may increase the immunosuppressive activities of Tofacitinib.	Approved, Investigational
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Tacrolimus.	Approved
Tolbutamide	The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Tacrolimus.	Approved
Tolciclate	The metabolism of Tacrolimus can be decreased when combined with Tolciclate.	Experimental
Tolfenamic Acid	Tolfenamic Acid may increase the nephrotoxic activities of Tacrolimus.	Approved
Tolmetin	Tolmetin may increase the nephrotoxic activities of Tacrolimus.	Approved
Tolnaftate	The metabolism of Tacrolimus can be decreased when combined with Tolnaftate.	Approved, Vet Approved
Tolvaptan	The serum concentration of Tolvaptan can be decreased when it is combined with Tacrolimus.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Tacrolimus.	Approved, Investigational
Toremifene	The serum concentration of Toremifene can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Tositumomab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Tositumomab.	Approved
Trabectedin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Trabectedin.	Approved, Investigational
Trandolapril	The metabolism of Tacrolimus can be decreased when combined with Trandolapril.	Approved
Tranilast	Tranilast may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Trastuzumab	Trastuzumab may increase the neutropenic activities of Tacrolimus.	Approved, Investigational
Trastuzumab emtansine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Trastuzumab emtansine.	Approved
Trazodone	The metabolism of Tacrolimus can be decreased when combined with Trazodone.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Tretinoin.	Approved, Investigational, Nutraceutical
Triamcinolone	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Triamcinolone.	Approved, Vet Approved
Triamterene	Triamterene may increase the hyperkalemic activities of Tacrolimus.	Approved
Tribenoside	Tribenoside may increase the nephrotoxic activities of Tacrolimus.	Experimental
Trifluoperazine	The serum concentration of Tacrolimus can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Tacrolimus can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimethoprim	The serum concentration of Tacrolimus can be decreased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimetrexate	The metabolism of Tacrolimus can be decreased when combined with Trimetrexate.	Approved, Investigational
Trimipramine	The serum concentration of Tacrolimus can be increased when it is combined with Trimipramine.	Approved
Triptolide	Triptolide may increase the nephrotoxic activities of Tacrolimus.	Investigational
Trofosfamide	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Trofosfamide.	Investigational
Troglitazone	The therapeutic efficacy of Troglitazone can be decreased when used in combination with Tacrolimus.	Withdrawn
Troleandomycin	The serum concentration of Tacrolimus can be increased when it is combined with Troleandomycin.	Approved
Tylosin	The serum concentration of Tacrolimus can be increased when it is combined with Tylosin.	Vet Approved
Ubenimex	The metabolism of Tacrolimus can be decreased when combined with Ubenimex.	Experimental
Ubidecarenone	The serum concentration of Ubidecarenone can be increased when it is combined with Tacrolimus.	Experimental
Ulinastatin	The metabolism of Tacrolimus can be decreased when combined with Ulinastatin.	Investigational
Ulipristal	The serum concentration of Ulipristal can be decreased when it is combined with Tacrolimus.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be decreased when it is combined with Tacrolimus.	Approved
Ustekinumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ustekinumab.	Approved, Investigational
Valdecoxib	Valdecoxib may increase the nephrotoxic activities of Tacrolimus.	Investigational, Withdrawn
Vecuronium	The serum concentration of Vecuronium can be decreased when it is combined with Tacrolimus.	Approved
Vedolizumab	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vedolizumab.	Approved
Velpatasvir	The serum concentration of Velpatasvir can be decreased when it is combined with Tacrolimus.	Approved
Venetoclax	The serum concentration of Venetoclax can be decreased when it is combined with Tacrolimus.	Approved
Venlafaxine	The metabolism of Tacrolimus can be decreased when combined with Venlafaxine.	Approved
Vilanterol	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vilanterol.	Approved
Vilazodone	The metabolism of Tacrolimus can be decreased when combined with Vilazodone.	Approved
Vildagliptin	The metabolism of Tacrolimus can be decreased when combined with Vildagliptin.	Approved, Investigational
Vinblastine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vinblastine.	Approved
Vincristine	The serum concentration of Vincristine can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Vincristine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vincristine.	Approved, Investigational
Vindesine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vindesine.	Approved
Vinorelbine	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vinorelbine.	Approved, Investigational
Vismodegib	The serum concentration of Vismodegib can be decreased when it is combined with Tacrolimus.	Approved
Voclosporin	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Voclosporin.	Investigational
Voglibose	The therapeutic efficacy of Voglibose can be decreased when used in combination with Tacrolimus.	Approved, Investigational
Voriconazole	The serum concentration of Tacrolimus can be increased when it is combined with Voriconazole.	Approved, Investigational
Vortioxetine	The metabolism of Tacrolimus can be decreased when combined with Vortioxetine.	Approved
Voxilaprevir	The serum concentration of Voxilaprevir can be decreased when it is combined with Tacrolimus.	Approved
Ximelagatran	The metabolism of Tacrolimus can be decreased when combined with Ximelagatran.	Approved, Investigational, Withdrawn
Yellow fever vaccine	The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Tacrolimus.	Approved
Z-Val-Ala-Asp fluoromethyl ketone	The metabolism of Tacrolimus can be decreased when combined with Z-Val-Ala-Asp fluoromethyl ketone.	Experimental
Zaltoprofen	Zaltoprofen may increase the nephrotoxic activities of Tacrolimus.	Approved
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Tacrolimus.	Approved
Zileuton	Zileuton may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational, Withdrawn
Zimelidine	The metabolism of Tacrolimus can be decreased when combined with Zimelidine.	Withdrawn
Ziprasidone	The metabolism of Tacrolimus can be decreased when combined with Ziprasidone.	Approved
Zofenopril	The metabolism of Tacrolimus can be decreased when combined with Zofenopril.	Experimental
Zomepirac	Zomepirac may increase the nephrotoxic activities of Tacrolimus.	Withdrawn
Zoster vaccine	The therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Tacrolimus.	Approved

Food Interactions

• Food, especially food with a high-fat content, decreases the rate and extent of absorption.
• The time of the meal affects tacrolimus bioavailability. Take tacrolimus capsules consistently everyday either with or without food.

References

Synthesis Reference

Pan Sup Chang, Hoon Cho, "Water soluble polymer-tacrolimus conjugated compounds and process for preparing the same." U.S. Patent US5922729, issued April, 1997.

US5922729

General References

1. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H: FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987 Sep;40(9):1249-55. [PubMed:2445721]
2. Pritchard DI: Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Discov Today. 2005 May 15;10(10):688-91. [PubMed:15896681]
3. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991 Aug 23;66(4):807-15. [PubMed:1715244]
4. Fukatsu S, Fukudo M, Masuda S, Yano I, Katsura T, Ogura Y, Oike F, Takada Y, Inui K: Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient. Drug Metab Pharmacokinet. 2006 Apr;21(2):122-5. [PubMed:16702731]
5. Hanifin JM, Paller AS, Eichenfield L, Clark RA, Korman N, Weinstein G, Caro I, Jaracz E, Rico MJ: Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol. 2005 Aug;53(2 Suppl 2):S186-94. [PubMed:16021174]

External Links

Human Metabolome Database

HMDB15002

KEGG Drug

D00107

KEGG Compound

C01375

PubChem Compound

445643

PubChem Substance

46506004

ChemSpider

393220

BindingDB

50030448

ChEBI

61049

ChEMBL

CHEMBL269732

Therapeutic Targets Database

DAP000162

PharmGKB

PA451578

HET

FK5

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Tacrolimus

ATC Codes

D11AH01 — Tacrolimus

• D11AH — Agents for dermatitis, excluding corticosteroids
• D11A — OTHER DERMATOLOGICAL PREPARATIONS
• D11 — OTHER DERMATOLOGICAL PREPARATIONS
• D — DERMATOLOGICALS

L04AD02 — Tacrolimus

• L04AD — Calcineurin inhibitors
• L04A — IMMUNOSUPPRESSANTS
• L04 — IMMUNOSUPPRESSANTS
• L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

AHFS Codes

• 92:44.00 — Immunosuppressive Agents
• 84:92.00 — Misc. Skin and Mucous Membrane Agents

PDB Entries

1bkf / 1fkf / 1fkj / 1q6i / 1tco / 1yat / 2fke / 2vn1 / 3ihz / 3o5r …

show 15 more

FDA label

Download (144 KB)

MSDS

Download (54.9 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Completed	Treatment	Transplantation, Stem Cell	1
0	Terminated	Treatment	Acute Kidney Injury (AKI)	1
0	Terminated	Treatment	Allogeneic peripheral haematopoietic stem cell transplant / Neuroepithelial Tumor / Tumors, Solid	1
0	Withdrawn	Treatment	Multiple Myeloma (MM) / Myeloma-Multiple	1
1	Active Not Recruiting	Treatment	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / CD45-Positive Neoplastic Cells Present / Chronic Myelomonocytic Leukemia / Previously Treated Myelodysplastic Syndromes / Refractory Anemia With Excess Blasts / Refractory Anemia With Ring Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts	1
1	Completed	Not Available	Drug Interactions / Healthy Volunteers / Pharmacokinetics of ASP015K	1
1	Completed	Not Available	Healthy Volunteers	2
1	Completed	Not Available	Healthy Volunteers / Pharmacokinetics of ASP015K and Tacrolimus	1
1	Completed	Not Available	Healthy Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Tacrolimus	1
1	Completed	Basic Science	Chronic Hepatitis C Infection	1
1	Completed	Basic Science	Drug Interactions / Hypercholesterolaemia / Immunosuppression / Pharmacokinetics	1
1	Completed	Basic Science	Healthy Volunteers	1
1	Completed	Basic Science	Healthy Volunteers / Pharmacokinetics / Venous Thromboembolism	1
1	Completed	Prevention	Healthy Volunteers	1
1	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
1	Completed	Treatment	Allogeneic Stem Cell Transplantation / Malignancies, Hematologic	1
1	Completed	Treatment	Atopic Dermatitis (AD)	1
1	Completed	Treatment	Blood And Marrow Transplantation / Leukemias / Malignant Lymphomas / Transplantation Infection / Transplantation, Bone Marrow	1
1	Completed	Treatment	Chronic Graft Versus Host Disease	1
1	Completed	Treatment	Chronic Hepatitis C Virus (HCV) Infection / Immunosuppression / Transplantation, Organ	1
1	Completed	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Small Intestine Cancer	1
1	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
1	Completed	Treatment	End-Stage Renal Disease (ESRD) / Impaired Renal Function / Nephritis, Lupus / Systemic Lupus Erythematosus (SLE)	1
1	Completed	Treatment	Graft Versus Host Disease (GVHD) / Peripheral Blood Stem Cell Transplantation / Transplantation, Homologous	1
1	Completed	Treatment	Healthy Volunteers	4
1	Completed	Treatment	Hepatitis C Virus (HCV)	1
1	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	2
1	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
1	Completed	Treatment	Leukemias / Myelodysplastic Syndrome	2
1	Completed	Treatment	Psoriasis	1
1	Completed	Treatment	Renal Replacement Therapies	1
1	Not Yet Recruiting	Treatment	Haemoglobinopathies congenital / Sickle Cell Disorders / Thalassaemic disorders	1
1	Recruiting	Diagnostic	Bioequivalence	1
1	Recruiting	Treatment	Acute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Adult Acute Lymphoblastic Leukemia in Complete Remission / Childhood Acute Lymphoblastic Leukemia in Complete Remission / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia	1
1	Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Malignancies, Hematologic / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Syndromes / Non Hodgkin Lymphoma (NHL)	1
1	Recruiting	Treatment	Agnogenic Myeloid Metaplasia / Leukemias / Malignant Lymphomas / Smith-Magenis Syndrome	1
1	Recruiting	Treatment	Amputations / Genital Diseases, Male / Urologic Injuries	1
1	Recruiting	Treatment	Castration-Resistant Prostate Carcinoma / Leukemia, Plasma Cell / Prostate Carcinoma Metastatic in the Bone / Recurrent Plasma Cell Myeloma / Stage IV Prostate Cancer	1
1	Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemias	1
1	Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Sickle Cell Disorders	1
1	Recruiting	Treatment	Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Hematologic Malignancy	1
1	Recruiting	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma	1
1	Recruiting	Treatment	Secondary Myelofibrosis	1
1	Recruiting	Treatment	Transplantation, Liver	1
1	Terminated	Treatment	Juvenile Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
1	Terminated	Treatment	Leukemias / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Smith-Magenis Syndrome	1
1	Unknown Status	Treatment	Ocular GVHD	1
1	Unknown Status	Treatment	Transplantation, Organ	1
1	Withdrawn	Supportive Care	Acute myeloid leukaemia (in remission) / Primary Myelofibrosis / Primary Myelofibrosis, Prefibrotic Stage / Secondary Acute Myeloid Leukemia / Secondary Myelofibrosis	1
1	Withdrawn	Treatment	Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides and Sezary Syndrome / Stage IIB Mycosis Fungoides and Sezary Syndrome / Stage IIIA Mycosis Fungoides and Sezary Syndrome / Stage IIIB Mycosis Fungoides and Sezary Syndrome / Stage IVA Mycosis Fungoides and Sezary Syndrome / Stage IVB Mycosis Fungoides and Sezary Syndrome	1
1	Withdrawn	Treatment	Leukemias / Malignant Lymphomas / Pediatric Disorders / Transplantation, Stem Cell	1
1	Withdrawn	Treatment	Scleroderma	1
1, 2	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Aggressive Non-Hodgkin Lymphoma / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Previously Treated Myelodysplastic Syndromes / Recurrent Chronic Lymphocytic Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Indolent Adult Non-Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Plasma Cell Myeloma / Refractory Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
1, 2	Active Not Recruiting	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
1, 2	Active Not Recruiting	Treatment	Complete Atypical DiGeorge Anomaly / Complete Atypical DiGeorge Syndrome / Complete DiGeorge Anomaly / Complete DiGeorge Syndrome / DiGeorge Anomaly	1
1, 2	Active Not Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes	1
1, 2	Active Not Recruiting	Treatment	Leukaemia, Acute / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Disease	1
1, 2	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	1
1, 2	Completed	Prevention	Malignancies, Hematologic	1
1, 2	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
1, 2	Completed	Treatment	CNI Side Effects	1
1, 2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Malignancies, Hematologic	1
1, 2	Completed	Treatment	Kidney Diseases / Renal Failure / Transplantation, Kidney	1
1, 2	Completed	Treatment	Kidney Diseases / Transplant, Kidney / Transplantation, Kidney / Transplantation, Renal	1
1, 2	Completed	Treatment	Kidney Diseases / Transplantation, Kidney	1
1, 2	Completed	Treatment	Leukemias	1
1, 2	Completed	Treatment	Leukemias / Malignant Lymphomas	1
1, 2	Completed	Treatment	Malignancies, Hematologic	3
1, 2	Not Yet Recruiting	Prevention	Graft Versus Host Disease (GVHD) / Lung Cancers	1
1, 2	Not Yet Recruiting	Treatment	Age-Related Macular Degeneration (ARMD)	1
1, 2	Recruiting	Basic Science	Transplantation, Kidney	1
1, 2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myeloid Leukemia (CML) / Juvenile Myelomonocytic Leukemia (JMML) / Lymphoma (Hodgkin's and Non-Hodgkin's) / Myelodysplastic Syndromes (MDS)	1
1, 2	Recruiting	Treatment	Adult Living Donor Kidney Transplant Recipients / Living Kidney Donors / Transplant, Kidney	1
1, 2	Recruiting	Treatment	Beta Thalassemia-Major / Sickle Cell Disorders	1
1, 2	Recruiting	Treatment	Diabetes, Diabetes Mellitus Type 1	1
1, 2	Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Malignancies, Hematologic / Relapses	1
1, 2	Recruiting	Treatment	Hematopoietic Stem Cell Transplantation (HSCT) / Multiple Myeloma (MM)	1
1, 2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic	1
1, 2	Recruiting	Treatment	Leukemias	2
1, 2	Recruiting	Treatment	Leukemias / Malignant Lymphomas	1
1, 2	Recruiting	Treatment	Leukemias / Myeloproliferative Disorders	1
1, 2	Recruiting	Treatment	Malignant Lymphomas	1
1, 2	Recruiting	Treatment	Scleroderma, Systemic / Severe Systemic Sclerosis	1
1, 2	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Hematologic Diseases / Lymphoproliferative Disorders / Multiple Myeloma (MM) / Myelodysplastic and Myeloproliferative Disorders / Plasma Cell Dyscrasia	1
1, 2	Terminated	Treatment	Graft Versus Host Disease (GVHD)	1
1, 2	Terminated	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
1, 2	Terminated	Treatment	Graft Versus Host Disease (GVHD) / Lupus Erythematosus	1
1, 2	Terminated	Treatment	Leukemias / Myeloproliferative Disorders / Plasma Cell Myeloma	1
1, 2	Unknown Status	Treatment	End Stage Renal Disease (ESRD) / Transplant, Kidney	1
1, 2	Unknown Status	Treatment	End-Stage Renal Disease (ESRD) / Renal Failure	1
1, 2	Unknown Status	Treatment	Leukaemia, Acute / Myelodysplastic Syndrome / Tumors, Solid	1
1, 2	Unknown Status	Treatment	Peripheral Nerve Injury (PNI)	1
1, 2	Withdrawn	Treatment	Multiple Myeloma (MM) / Refractory Multiple Myeloma	1
2	Active Not Recruiting	Other	Heart Transplantation / Transplantation, Kidney / Transplantation, Liver	1
2	Active Not Recruiting	Prevention	Acute Graft Versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation / Hematopoietic Stem Cell Transplantation (HSCT)	1
2	Active Not Recruiting	Prevention	Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Leukaemia, Acute / Lymphoma, B-Cell / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Myelodysplasia / Small Lymphocytic Lymphoma (SLL)	1
2	Active Not Recruiting	Prevention	Graft Versus Host Disease (GVHD)	2
2	Active Not Recruiting	Prevention	Graft Versus Host Disease (GVHD) / Neoplasms, Hematologic / Non-Neoplastic Hematologic and Lymphocytic Disorder	1
2	Active Not Recruiting	Prevention	Heart Transplantation / Intestine Transplantation / Transplantation, Kidney / Transplantation, Liver / Transplantation, Lung	1
2	Active Not Recruiting	Treatment	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Biphenotypic Leukemia (ABL) / Acute Leukemias of Ambiguous Lineage / Acute myeloid leukaemia (in remission) / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / RAEB-1 / RAEB-2 / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Adult Acute Lymphoblastic Leukemia / Refractory Anemia With Excess Blasts / Refractory Childhood Acute Lymphoblastic Leukemia	1
2	Active Not Recruiting	Treatment	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3- / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Lymphoma / Childhood Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Burkitt Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Plasma Cell Myeloma / Secondary Myelodysplastic Syndromes / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Immunoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Burkitt Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Contiguous Immunoblastic Lymphoma / Stage II Adult Non-Contiguous Immunoblastic Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Burkitt Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Burkitt Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma / Stage II Contiguous Adult Diffuse Small Cleaved Cell Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage II Non-Contiguous Adult Burkitt Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage II Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Burkitt Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Burkitt Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
2	Active Not Recruiting	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Aplastic Anaemia (AA) / Burkitt's Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Congenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Paroxysmal Nocturnal Haemoglobinuria (PNH) / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Severe Combined Immunodeficiency / Severe Congenital Neutropenia / Shwachman-Diamond Syndrome / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM) / Wiskott-Aldrich Syndrome (WAS)	1
2	Active Not Recruiting	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Leukemia, Prolymphocytic / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Small Lymphocytic Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Multiple Myeloma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Small Lymphocytic Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome / Testicular Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies / Waldenstrom's Macroglobulinemia (WM)	1
2	Active Not Recruiting	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Waldenstrom's Macroglobulinemia (WM)	1
2	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia	1
2	Active Not Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome RAEB 1 / Myelodysplastic Syndrome RAEB 2	1
2	Active Not Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Disorders / Non-Hodgkin's Lymphoma (NHL)	1
2	Active Not Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Immune System Diseases / Leukemia Acute Myeloid Leukemia (AML) / Malignant Lymphomas / Myelodysplastic Syndromes	1
2	Active Not Recruiting	Treatment	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia in Remission	1
2	Active Not Recruiting	Treatment	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia	1
2	Active Not Recruiting	Treatment	Adult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia	1
2	Active Not Recruiting	Treatment	Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / De Novo Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia	1
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)	1
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Low-Grade / Lymphoma, Mantle-Cell / Small Lymphocytic Lymphoma (SLL) / T-Cell Lymphomas	1
2	Active Not Recruiting	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition	1
2	Active Not Recruiting	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	2
2	Active Not Recruiting	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Active Not Recruiting	Treatment	Graft Versus Host Disease (GVHD)	2
2	Active Not Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas	1
2	Active Not Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes	1
2	Active Not Recruiting	Treatment	Juvenile Myelomonocytic Leukemia	1
2	Active Not Recruiting	Treatment	Leukemias	1
2	Active Not Recruiting	Treatment	Leukemias / Malignant Lymphomas	2
2	Active Not Recruiting	Treatment	Leukemias / Malignant Lymphomas / Transplantation, Stem Cell	1
2	Active Not Recruiting	Treatment	Transplantation, Kidney	1
2	Completed	Not Available	Atopic Dermatitis (AD)	1
2	Completed	Prevention	Acute Graft Versus Host Disease	1
2	Completed	Prevention	Acute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)	1
2	Completed	Prevention	Acute Lymphoblastic Leukaemias (ALL) / Hodgkins Disease (HD) / Malignancies, Hematologic / Myelodysplastic Syndrome / Myelogenous Leukemia / Non-Hodgkin's Lymphoma (NHL)	1
2	Completed	Prevention	Chronic Hepatitis C Infection / Transplantation, Liver	1
2	Completed	Prevention	Chronic Lung Diseases	1
2	Completed	Prevention	De Novo Kidney Transplantation	1
2	Completed	Prevention	Diabetes, Diabetes Mellitus Type 1	1
2	Completed	Prevention	Heart Transplantation / Pancreas (Including SPK) Transplantation / Transplantation, Lung	1
2	Completed	Prevention	Immunosuppression / Kidney Failure,Chronic / Transplantation, Kidney	1
2	Completed	Prevention	Liver Dysfunction / Rejection, Transplant / Transplantation, Liver	1
2	Completed	Prevention	Transplantation, Kidney	3
2	Completed	Prevention	Transplantation, Liver	2
2	Completed	Supportive Care	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Atypical Chronic Myeloid Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extramedullary Plasmacytoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Hematopoietic/Lymphoid Cancer / Isolated Plasmacytoma of Bone / Juvenile Myelomonocytic Leukemia / Meningeal Chronic Myelogenous Leukemia / Myelodysplastic/Myeloproliferative Disease, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Multiple Myeloma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma	1
2	Completed	Supportive Care	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Intraocular Lymphoma / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Post-Transplant Lymphoproliferative Disorder / Primary Central Nervous System Hodgkin Lymphoma / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ringed Sideroblasts / Refractory Chronic Lymphocytic Leukemia / Refractory Cytopenia With Multilineage Dysplasia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Central Nervous System Hodgkin Lymphoma / Secondary Central Nervous System Non-Hodgkin Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
2	Completed	Supportive Care	Cancer, Breast / Cancer, Ovarian / Chronic Myeloproliferative Disorders / Gestational Trophoblastic Disease / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Neuroblastomas / Testicular germ cell tumour	1
2	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Infection NOS / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions / Secondary Myelofibrosis / Small Intestine Cancer	1
2	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hematopoietic/Lymphoid Cancer / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
2	Completed	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
2	Completed	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Hematopoietic/Lymphoid Cancer / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia	1
2	Completed	Treatment	Acute Lymphocytic Leukemia (ALL) / Aplastic Anaemia (AA) / Biphenotypic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Hodgkins Disease (HD) / Leukemia Acute Myeloid Leukemia (AML) / Malignant Lymphomas / Myelodysplastic Syndromes / Plasma Cell Neoplasms	1
2	Completed	Treatment	Adult Acute Lymphoblastic Leukemia in Remission	1
2	Completed	Treatment	Amyotrophic Lateral Sclerosis (ALS)	1
2	Completed	Treatment	Atopic Dermatitis (AD)	5
2	Completed	Treatment	Blood Stem Cell Transplant Failure / Leukemias / Malignancies, Hematologic	1
2	Completed	Treatment	Bronchial Asthma	2
2	Completed	Treatment	Chronic Myelogenous Leukemia (CML) / Leukemias	1
2	Completed	Treatment	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
2	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Crohn's Disease (CD)	1
2	Completed	Treatment	Diabetes Mellitus, Insulin-Dependent	1
2	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1	3
2	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1 / Hypoglycemia / Metabolic Diseases	1
2	Completed	Treatment	Disorder Related to Renal Transplantation	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD)	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Secondary Myelofibrosis	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Malignancies, Hematologic	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Malignant Lymphomas	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD) / Transplantation, Bone Marrow	2
2	Completed	Treatment	Haematological Malignancies	1
2	Completed	Treatment	Heart Transplantation / Transplantation, Kidney / Transplantation, Liver	1
2	Completed	Treatment	Hepatic Failure	2
2	Completed	Treatment	Hepatitis C, Chronic	1
2	Completed	Treatment	Hepatitis, Autoimmune	1
2	Completed	Treatment	Hepatocellular,Carcinoma	1
2	Completed	Treatment	Hodgkins Disease (HD)	1
2	Completed	Treatment	Hodgkins Disease (HD) / Leukaemia, Lymphoblastic / Multiple Myeloma (MM) / Myelogenous Leukemia / Non-Hodgkin's Lymphoma (NHL)	1
2	Completed	Treatment	IgA Nephropathy	1
2	Completed	Treatment	Kidney Diseases	1
2	Completed	Treatment	Kidney Failure,Chronic / Transplantation, Kidney	1
2	Completed	Treatment	Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Myeloproliferative Neoplasms / Plasma Cell Neoplasms	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	2
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Myeloproliferative Disorders / Renal Cancers	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndrome	1
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes	2
2	Completed	Treatment	Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Completed	Treatment	Liver Diseases / Transplantation, Liver	1
2	Completed	Treatment	Malignancies, Hematologic	1
2	Completed	Treatment	Multiple Myeloma (MM) / Plasma Cell Neoplasms	1
2	Completed	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
2	Completed	Treatment	Neoplasms, Malignant	1
2	Completed	Treatment	Oral Chronic Graft-Versus-Host Disease	1
2	Completed	Treatment	Oral Lichen Planus	1
2	Completed	Treatment	Renal Cancers	2
2	Completed	Treatment	Renal Failure	3
2	Completed	Treatment	Sarcomas	1
2	Completed	Treatment	Transplant, Kidney	1
2	Completed	Treatment	Transplantation, Kidney	4
2	Completed	Treatment	Transplantation, Liver	2
2	Completed	Treatment	Vulvar Lichen Sclerosus	1
2	Not Yet Recruiting	Treatment	Hematopoietic/Lymphoid Cancer	1
2	Recruiting	Prevention	Acute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)	1
2	Recruiting	Prevention	Acute myeloid leukaemia (in remission) / Adult Acute Lymphoblastic Leukemia in Complete Remission / Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission / Chronic Myelomonocytic Leukemia in Remission / Graft Versus Host Disease (GVHD) / Lymphoma, Hodgkins / Minimal Residual Disease / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma / Severe Aplastic Anemia (SAA) / Waldenstrom's Macroglobulinemia (WM)	1
2	Recruiting	Prevention	Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Follicular Lymphoma (FL) / Graft Versus Host Disease (GVHD) / Leukaemia, Acute / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Small Lymphocytic Lymphoma (SLL)	1
2	Recruiting	Prevention	Chronic Myeloid Leukemia (CML) / Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Myelodysplastic Syndromes	1
2	Recruiting	Prevention	Graft Versus Host Disease (GVHD)	1
2	Recruiting	Prevention	Graft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT)	1
2	Recruiting	Supportive Care	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Follicular Lymphoma (FL) / Graft Versus Host Disease (GVHD) / Leukaemia, Acute / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma / Secondary Myelodysplastic Syndromes	1
2	Recruiting	Treatment	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Biphenotypic Leukemia (ABL) / Acute Leukemias of Ambiguous Lineage / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Graft Versus Host Disease (GVHD) / Lymphoma, Lymphoblastic / Myelodysplastic Syndrome With Excess Blasts / Myelodysplastic Syndrome With Excess Blasts-1 / Myelodysplastic Syndrome With Excess Blasts-2 / RAEB-1 / RAEB-2 / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Anemia With Excess Blasts	1
2	Recruiting	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Cytopenia With Multilineage Dysplasia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
2	Recruiting	Treatment	Acute Biphenotypic Leukemia (ABL) / Acute Erythroid Leukemia in Remission / Acute Leukemia in Remission / Acute Megakaryoblastic Leukemia / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Acute Myeloid Leukemia With FLT3/ITD Mutation / Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 / Acute Myeloid Leukemia With Inv(3)(q21q26.2); RPN1-EVI1 / Acute Myeloid Leukemia With Multilineage Dysplasia / Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214 / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Complete Remission / B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) / B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Burkitt's Lymphoma / Childhood Acute Lymphoblastic Leukemia in Complete Remission / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Myelodysplastic Syndrome / Recurrent Anaplastic Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma / Secondary Acute Myeloid Leukemia / T Lymphoblastic Lymphoma	1
2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Chronic Myeloid Leukemia (CML) / Granulocytic Sarcoma / Juvenile Myelomonocytic Leukemia (JMML) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL)	1
2	Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Burkitt's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Hematological Diseases / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Lymphoma, B-Cell / Lymphoma, Lymphoblastic / Lymphoma, Mantle-Cell / Lymphoplasmacytic Lymphoma / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Myeloproliferative Syndromes / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL)	1
2	Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Syndromes / Non-Hodgkin's Lymphoma (NHL) / Other Diseases of Blood and Blood-Forming Organs	1
2	Recruiting	Treatment	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Secondary Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia in Remission / Secondary Myelodysplastic Syndromes / Therapy-Related Myelodysplastic Syndrome	1
2	Recruiting	Treatment	Acute myeloid leukaemia (in remission) / Aplastic Anaemia (AA) / Chronic Myelomonocytic Leukemia / Indolent Non-Hodgkin's Lymphomas / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Neoplasms, Malignant / Plasma Cell Myeloma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ring Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts	1
2	Recruiting	Treatment	Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Aplastic Anaemia (AA) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Essential Thrombocythemia (ET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Anemia / Refractory Anemia With Ringed Sideroblasts / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Urticaria Pigmentosa / Waldenstrom's Macroglobulinemia (WM)	1
2	Recruiting	Treatment	Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Chronic Myelomonocytic Leukemia / Chronic Myeloproliferative Disorders / Essential Thrombocythemia (ET) / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myelodysplastic Syndromes / Plasma Cell Dyscrasia / Plasma Cell Neoplasms / Polycythemia Vera (PV) / Small Lymphocytic Lymphoma (SLL)	1
2	Recruiting	Treatment	Aplastic Anaemia (AA) / Bone Marrow Failure / Immunosuppression / Severe Aplastic Anemia (SAA)	1
2	Recruiting	Treatment	Aplastic Anaemia (AA) / Immunodeficiency Syndrome / Non-Cancer Diagnosis / Severe Aplastic Anemia (SAA)	1
2	Recruiting	Treatment	B-Cell Prolymphocytic Leukemia / Hypodiploidy / Leukemia, Plasma Cell / Loss of Chromosome 17p / Progression of Multiple Myeloma or Plasma Cell Leukemia / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Non-Hodgkin's lymphoma / Refractory Plasma Cell Myeloma / Refractory Small Lymphocytic Lymphoma / T(14;16) / T(4;14) / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)	1
2	Recruiting	Treatment	Bone Marrow Failure Syndromes / Severe Aplastic Anemia (SAA)	1
2	Recruiting	Treatment	Chronic Myelogenous Leukemia (CML) / Chronic Myelomonocytic Leukemia (CMML) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)	1
2	Recruiting	Treatment	Chronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
2	Recruiting	Treatment	Delayed Graft Function / Transplant, Kidney	1
2	Recruiting	Treatment	Epidermolysis Bullosa	1
2	Recruiting	Treatment	Fibrolamellar Hepatocellular Carcinoma / Hepatocellular Carcinoma (Fibrolamellar Variant) / Hepatocellular,Carcinoma	1
2	Recruiting	Treatment	Focal Segmental Glomerulosclerosis (FSGS) / Transplantation, Kidney	1
2	Recruiting	Treatment	Graft Survival / HLA-mismatched Bone Marrow Transplantation / Myeloablative Conditioning / Transplantion, Bone Marrow	1
2	Recruiting	Treatment	Haematological Malignancies	1
2	Recruiting	Treatment	Hematopoietic and Lymphoid Cell Neoplasm	1
2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML)	1
2	Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes	1
2	Recruiting	Treatment	Leukemias	1
2	Recruiting	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
2	Recruiting	Treatment	Non-Malignant	1
2	Recruiting	Treatment	Orthotopic Liver Transplant	1
2	Recruiting	Treatment	Primary Myelofibrosis / Secondary Myelofibrosis	1
2	Recruiting	Treatment	Severe Aplastic Anemia (SAA)	1
2	Recruiting	Treatment	Sickle Cell Disorders	1
2	Recruiting	Treatment	Transplant, Kidney	1
2	Recruiting	Treatment	Transplantation, Kidney	1
2	Suspended	Treatment	Crohn's Disease (CD)	1
2	Terminated	Prevention	Acute Leukemia in Remission / Leukemia, Myeloid, Accelerated-Phase / Leukemia, Myeloid, Chronic-Phase / Myelodysplastic Syndromes	1
2	Terminated	Prevention	Cardiac Allograft Vasculopathy / Heart Transplant Recipients	1
2	Terminated	Prevention	Graft Versus Host Disease (GVHD)	1
2	Terminated	Prevention	Immunosuppression in Solid Organ Transplant	1
2	Terminated	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
2	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myelocytic Leukemia / Chronic Myelocytic Leukemia / Granulocytic Sarcoma / Hodgkin's or Non-Hodgkin's Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome	1
2	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / All / Chronic Lymphocytic Leukaemia (CLL) / CLL / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Lymphoma, Hodgkins / Malignancies, Hematologic / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma	1
2	Terminated	Treatment	Aplastic Anaemia (AA)	1
2	Terminated	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood	1
2	Terminated	Treatment	End-Stage Renal Disease (ESRD)	1
2	Terminated	Treatment	Haematological Malignancies	1
2	Terminated	Treatment	Haemoglobinopathies congenital / Hemoglobin SC Disease / Sickle Cell Disorders / Thalassaemic disorders / Thalassemia Major (TM)	1
2	Terminated	Treatment	Leukemias	1
2	Terminated	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myeloproliferative Disorders	1
2	Terminated	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndrome	1
2	Terminated	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Terminated	Treatment	Leukemias / Malignant Lymphomas / Myeloproliferative Disorders / Plasma Cell Myeloma	1
2	Terminated	Treatment	Malignant Lymphomas	1
2	Terminated	Treatment	New Onset Diabetes Mellitus After Renal Transplantation	1
2	Terminated	Treatment	Primary Renal Allograft Candidate / Transplantation, Kidney	1
2	Terminated	Treatment	Primary Simultaneous Kidney and Pancreas Allograft Candidates / Simultaneous Kidney and Pancreas Transplantation	1
2	Terminated	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Terminated	Treatment	Sickle Cell Disorders	1
2	Terminated	Treatment	Transplantation, Kidney / Transplantation, Renal	1
2	Unknown Status	Supportive Care	Acute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome	1
2	Unknown Status	Treatment	Acute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndrome	1
2	Unknown Status	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Malignant Plasma Cell Neoplasms / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Secondary Myelofibrosis	1
2	Unknown Status	Treatment	Conjunctivitis, Seasonal Allergic	1
2	Unknown Status	Treatment	Disseminated Sclerosis	1
2	Unknown Status	Treatment	Kidney Diseases	1
2	Unknown Status	Treatment	Leukemias / Malignant Lymphomas	1
2	Unknown Status	Treatment	Nephritis, Lupus	1
2	Withdrawn	Supportive Care	Graft Versus Host Disease (GVHD) / Leukemias	1
2	Withdrawn	Treatment	Accelerated Phase Chronic Myelogenous Leukemia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
2	Withdrawn	Treatment	Age-Related Macular Degeneration (ARMD)	1
2	Withdrawn	Treatment	Anemias / Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases	1
2	Withdrawn	Treatment	Colitis / Cytokines / Drug Evaluation / Hermanski-Pudlak Syndrome / Lymphocytes	1
2	Withdrawn	Treatment	Diabetes, Diabetes Mellitus Type 1	1
2	Withdrawn	Treatment	Neuroblastomas	1
2	Withdrawn	Treatment	Renal Cancers	1
2	Withdrawn	Treatment	Scleroderma, Systemic	1
2, 3	Active Not Recruiting	Treatment	Chronic Graft Versus Host Disease	1
2, 3	Active Not Recruiting	Treatment	Transplantation, Kidney	1
2, 3	Completed	Prevention	Graft Versus Host Disease (GVHD)	1
2, 3	Completed	Treatment	Glomerulonephritis minimal lesion	1
2, 3	Completed	Treatment	Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes	1
2, 3	Completed	Treatment	Maintenance With Tacrolimus / Pediatric Patients / Transplantation, Kidney	1
2, 3	Completed	Treatment	Vernal Keratoconjunctivitis	1
2, 3	Recruiting	Treatment	Amputation, Traumatic/Surgery / Amputations / Penis/Injuries / Penis/Surgery / Penis/Transplantation / Traumatic Amputations / Urologic Surgical Procedures, Male / Wounds and Injuries	1
2, 3	Recruiting	Treatment	Delayed Graft Function	1
2, 3	Recruiting	Treatment	Liver Diseases	1
2, 3	Terminated	Treatment	Follicular Lymphoma (FL) / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma	1
2, 3	Terminated	Treatment	Graft Failure / Ischemia Reperfusion Injury / Poor Graft Quality / Terminal Liver Disease / Transplant dysfunction	1
2, 3	Terminated	Treatment	Graft Versus Host Disease (GVHD)	1
2, 3	Terminated	Treatment	Hypertensive	1
2, 3	Terminated	Treatment	Pigmentation Disorders / Vitiligo	1
2, 3	Unknown Status	Treatment	Dermatomyositis / Pneumonitis, Interstitial / Polymyositis	1
2, 3	Unknown Status	Treatment	Rasmussen's Encephalitis	1
3	Active Not Recruiting	Treatment	B-cell Childhood Acute Lymphoblastic Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Graft Versus Host Disease (GVHD) / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia	1
3	Active Not Recruiting	Treatment	Disorder Related to Bone Marrow Transplantation / Leukemias / Transplantation Infection	1
3	Active Not Recruiting	Treatment	End Stage Renal Disease (ESRD) / Rejection of Renal Transplant	1
3	Active Not Recruiting	Treatment	Transplantation, Kidney	2
3	Completed	Not Available	Pharmacokinetics / Tacrolimus	1
3	Completed	Not Available	Transplantation, Liver	1
3	Completed	Basic Science	Renal Failure	1
3	Completed	Prevention	Graft Versus Host Disease (GVHD) / Survival	1
3	Completed	Prevention	Immunosuppression / Obliterative Bronchiolitis	1
3	Completed	Prevention	Renal Failure	1
3	Completed	Prevention	Transplantation, Kidney	6
3	Completed	Prevention	Transplantation, Liver	3
3	Completed	Supportive Care	Graft Versus Host Disease (GVHD)	1
3	Completed	Treatment	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Acute Myeloid Leukemia/Transient Myeloproliferative Disorder / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes	1
3	Completed	Treatment	Atopic Dermatitis (AD)	4
3	Completed	Treatment	Chronic Hepatitis C Infection / Liver Cirrhosis	1
3	Completed	Treatment	Conjunctivitis / Keratoconjunctivitis	1
3	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1	1
3	Completed	Treatment	Glomerulonephritis minimal lesion	2
3	Completed	Treatment	Glomerulonephritis minimal lesion / Kidney Diseases / Tacrolimus	1
3	Completed	Treatment	Glomerulonephritis, Membranous / Nephritis, Lupus	1
3	Completed	Treatment	Heart Diseases / Heart Transplantation	1
3	Completed	Treatment	Heart Transplantation / Transplantation, Kidney / Transplantation, Liver	1
3	Completed	Treatment	Hepatocellular,Carcinoma	1
3	Completed	Treatment	Host vs Graft Reaction / Transplantation Immunology / Transplantation, Kidney	1
3	Completed	Treatment	Host vs Graft Reaction / Transplantation Immunology / Transplantation, Liver	1
3	Completed	Treatment	Induction Phase / Kidney Diseases / Maintenance Phase / Nephritis, Lupus / Tacrolimus	1
3	Completed	Treatment	Kidney Diseases	1
3	Completed	Treatment	Kidney-Pancreas Transplantation	1
3	Completed	Treatment	Leukemia, Lymphocytic, Acute / Leukemia, Myelocytic, Acute / Leukemia,Myeloid, Chronic / Myelodysplastic Syndromes	1
3	Completed	Treatment	Liver Transplant Recipients	1
3	Completed	Treatment	Lymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)	1
3	Completed	Treatment	Myasthenia Gravis	3
3	Completed	Treatment	Nephritis, Lupus	2
3	Completed	Treatment	Psoriasis	3
3	Completed	Treatment	Renal Failure	2
3	Completed	Treatment	Renal Failure / Tremors	1
3	Completed	Treatment	Rheumatoid Arthritis	2
3	Completed	Treatment	Skin Cancers / Transplantation, Kidney	1
3	Completed	Treatment	Transplant, Kidney	2
3	Completed	Treatment	Transplant; Failure, Kidney	1
3	Completed	Treatment	Transplantation, Kidney	5
3	Completed	Treatment	Transplantation, Liver	7
3	Completed	Treatment	Transplantation, Renal	1
3	Completed	Treatment	Transplantations	3
3	Completed	Treatment	Ulcerative Colitis (UC)	2
3	Enrolling by Invitation	Not Available	Diabetes, Diabetes Mellitus Type 1 / Islet Transplantation	1
3	Not Yet Recruiting	Prevention	Transplantation, Liver	1
3	Not Yet Recruiting	Treatment	Medication Adherence	1
3	Not Yet Recruiting	Treatment	Ulcerative Colitis (UC)	1
3	Recruiting	Prevention	Acute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
3	Recruiting	Prevention	Leukaemia, Acute / Myelodysplasia	1
3	Recruiting	Supportive Care	Acute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukaemias (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Leukemia Acute Myeloid Leukemia (AML) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL)	1
3	Recruiting	Treatment	Absolute Uterine Factor Infertility / Infertility, Female / Mayer Rokitansky Kuster Hauser Syndrome / Mullerian Aplasia / Uterus Absence, Acquired / Uterus; Absence, Congenital	1
3	Recruiting	Treatment	Chronic Kidney Disease (CKD)	1
3	Recruiting	Treatment	Diabetes, Diabetes Mellitus Type 1	1
3	Recruiting	Treatment	Failing Renal Allograft / Transplant, Kidney	1
3	Recruiting	Treatment	Glomerulonephritis membranous	1
3	Recruiting	Treatment	Graft Versus Host Disease (GVHD)	1
3	Recruiting	Treatment	Nephritis, Lupus	1
3	Recruiting	Treatment	Severe Seborrheic Dermatitis	1
3	Recruiting	Treatment	Transplantation, Liver	1
3	Recruiting	Treatment	Vitiligo	1
3	Suspended	Treatment	Transplant, Kidney	1
3	Terminated	Prevention	Evidence of Liver Transplantation	1
3	Terminated	Prevention	Transplantation, Lung	1
3	Terminated	Treatment	Atherosclerosis / Renal Failure	1
3	Terminated	Treatment	End-Stage Renal Disease (ESRD) / Transplantation, Kidney	1
3	Terminated	Treatment	Function of Renal Transplant	1
3	Terminated	Treatment	Nephritis, Lupus	1
3	Withdrawn	Prevention	Transplantation, Renal	1
3	Withdrawn	Treatment	Nephritis, Lupus	1
4	Active Not Recruiting	Prevention	Heart Transplantation / Transplantation, Kidney / Transplantation, Liver	1
4	Active Not Recruiting	Supportive Care	Cardiovascular Disease (CVD) / Immunosuppression / Transplantation, Kidney	1
4	Active Not Recruiting	Supportive Care	Renal Diseases / Transplant, Kidney	1
4	Active Not Recruiting	Treatment	Chronic Kidney Disease (CKD) / End Stage Renal Disease (ESRD) / Hemodialysis-dependent patients / Renal Replacement Therapies / Transplantation, Renal	1
4	Active Not Recruiting	Treatment	Glomerulonephritis, Membranous / Nephrotic Syndrome Secondary to Idiopathic Membranous Glomerulonephritis	1
4	Active Not Recruiting	Treatment	Pancreas Transplantation / Transplantation, Kidney	1
4	Active Not Recruiting	Treatment	Transplantation, Renal	1
4	Completed	Not Available	End Stage Renal Disease (ESRD)	1
4	Completed	Not Available	Function of Renal Transplant	1
4	Completed	Basic Science	End Stage Renal Disease (ESRD)	1
4	Completed	Basic Science	Pharmacokinetics Study in de Novo Kidney Transplantation	1
4	Completed	Health Services Research	Kidney Failure,Chronic	1
4	Completed	Prevention	Disorder Related to Cardiac Transplantation	1
4	Completed	Prevention	Disorder Related to Renal Transplantation	1
4	Completed	Prevention	Erectile Dysfunction (ED) / Prostate Cancer	1
4	Completed	Prevention	Heart Transplantation / Transplantation, Kidney / Transplantation, Liver	1
4	Completed	Prevention	Kidney Transplantion / Renal Transplantion	1
4	Completed	Prevention	Post Transplant Diabetes Mellitus	1
4	Completed	Prevention	Rejection, Transplant / Renal Allograft Recipients / Transplant, Kidney	1
4	Completed	Prevention	Rejection, Transplant / Transplantation, Kidney	1
4	Completed	Prevention	Transplant, Kidney	1
4	Completed	Prevention	Transplantation, Kidney	3
4	Completed	Prevention	Transplantation, Liver	1
4	Completed	Prevention	Transplantation, Renal	1
4	Completed	Supportive Care	Chronic Hepatitis C Infection / Renal Allograft	1
4	Completed	Treatment	Adult Primary Kidney Transplantation	1
4	Completed	Treatment	Atopic Dermatitis (AD)	8
4	Completed	Treatment	Chronic Hepatitis C Infection	1
4	Completed	Treatment	Chronic Hepatitis C Infection / End Stage Liver Diseases / Transplantation, Liver	1
4	Completed	Treatment	Chronic Hepatitis C Infection / Transplantation, Liver	1
4	Completed	Treatment	Chronic Renal Allograft Failure / Transplantation, Renal	1
4	Completed	Treatment	Chronic Renal Diseases	1
4	Completed	Treatment	Chronic Renal Failure (CRF)	1
4	Completed	Treatment	Complication of Transplant	1
4	Completed	Treatment	Complications of Transplanted Organs and Tissue / Diabetes Mellitus Nos New Onset	1
4	Completed	Treatment	De Novo Kidney Transplantation	1
4	Completed	Treatment	Diabetic Nephropathies / Transplant, Kidney / Type 2 Diabetes Mellitus	1
4	Completed	Treatment	Disorder Related to Renal Transplantation / Infections, Cytomegalovirus	1
4	Completed	Treatment	Dry Eye Syndrome (DES) / Sjögren's Syndrome	1
4	Completed	Treatment	End Stage Renal Disease (ESRD)	2
4	Completed	Treatment	End-Stage Renal Disease (ESRD)	1
4	Completed	Treatment	Glomerulonephritis minimal lesion	1
4	Completed	Treatment	Graft Versus Host Disease (GVHD)	1
4	Completed	Treatment	Graft Versus Host Disease (GVHD) / Renal Failure	1
4	Completed	Treatment	Henoch-Schönlein Purpura Nephritis	1
4	Completed	Treatment	Immunosuppression	1
4	Completed	Treatment	Infections, Cytomegalovirus / Renal Transplant Failure / Transplant; Complication, Rejection	1
4	Completed	Treatment	Ischemia Reperfusion Injury	1
4	Completed	Treatment	Kidney Diseases	1
4	Completed	Treatment	Kidney Failure,Chronic / Renal Insufficiency,Chronic / Transplantation, Kidney	1
4	Completed	Treatment	Kidney Pancreas Transplant / Transplant, Kidney	1
4	Completed	Treatment	Kidney Transplant Recipients / Liver Transplant Recipients	1
4	Completed	Treatment	Kidney Transplantation, Renal Transplantation	1
4	Completed	Treatment	Liver Cirrhosis / Liver Transplant Disorder	1
4	Completed	Treatment	Lupus Erythematosus, Systemic / Nephritis, Lupus	1
4	Completed	Treatment	MCNS / Minimal Change Nephrotic Syndrome (MCNS)	1
4	Completed	Treatment	Moderate/Severe Atopic Dermatitis	1
4	Completed	Treatment	Nephritis, Lupus	3
4	Completed	Treatment	Organ or Tissue Transplant; Complications	1
4	Completed	Treatment	Pityriasis Alba	1
4	Completed	Treatment	Polyomavirus Infections	1
4	Completed	Treatment	Rejection, Transplant / Renal Failure / Transplantation, Kidney	1
4	Completed	Treatment	Rheumatoid Arthritis	4
4	Completed	Treatment	Seborrheic Dermatitis	1
4	Completed	Treatment	Skin Inflammation	1
4	Completed	Treatment	Stable Renal Recipients / Transplantation, Kidney / Transplantation, Renal	1
4	Completed	Treatment	Transplant, Kidney	4
4	Completed	Treatment	Transplantation, Kidney	12
4	Completed	Treatment	Transplantation, Kidney / Transplantation, Liver	1
4	Completed	Treatment	Transplantation, Kidney / Transplantations	1
4	Completed	Treatment	Transplantation, Liver	7
4	Completed	Treatment	Transplantation, Renal	5
4	Completed	Treatment	Uveitis	1
4	Completed	Treatment	De Novo Liver Transplant Subjects	1
4	Not Yet Recruiting	Other	Kidney / Pharmacokinetics / Transplantations	1
4	Not Yet Recruiting	Treatment	Cardiac Transplant Rejection / Kidney Transplant Rejection / Liver Transplant Rejection	1
4	Not Yet Recruiting	Treatment	Disorder Related to Renal Transplantation / Immunosuppression Related Infectious Disease / Virus Diseases	1
4	Not Yet Recruiting	Treatment	Immunosuppression After Renal Transplantation / Transplant, Kidney	1
4	Not Yet Recruiting	Treatment	Kidney Transplant Failure and Rejection	1
4	Not Yet Recruiting	Treatment	Renal Transplant Patients	1
4	Not Yet Recruiting	Treatment	Transplantation, Liver	1
4	Recruiting	Other	Transplantation, Liver	1
4	Recruiting	Prevention	End-Stage Renal Disease (ESRD)	1
4	Recruiting	Treatment	Adherence to Medication Regime	1
4	Recruiting	Treatment	CYCLOSPORINE/TACROLIMUS	1
4	Recruiting	Treatment	Drug Interaction Potentiation / Transplantation, Kidney	1
4	Recruiting	Treatment	EBV / Transplant; Failure, Kidney	1
4	Recruiting	Treatment	End Stage Renal Disease (ESRD)	1
4	Recruiting	Treatment	Function of Renal Transplant	1
4	Recruiting	Treatment	Glomerulonephritis minimal lesion	2
4	Recruiting	Treatment	Heart Failure, Unspecified	1
4	Recruiting	Treatment	Hepatitis B Virus Associated Nephrotic Syndrome	1
4	Recruiting	Treatment	Hepatocellular,Carcinoma	1
4	Recruiting	Treatment	Immunosuppression	1
4	Recruiting	Treatment	Implant or Graft; Rejection	1
4	Recruiting	Treatment	Kidney Transplant Rejection / Other Complications of Kidney Transplant	1
4	Recruiting	Treatment	Liver Dysfunction	1
4	Recruiting	Treatment	Nephritis, Lupus	1
4	Recruiting	Treatment	Rheumatoid Arthritis	1
4	Recruiting	Treatment	Thalassemia Major (TM)	1
4	Recruiting	Treatment	Transplant, Kidney	1
4	Recruiting	Treatment	Transplantation, Kidney	2
4	Recruiting	Treatment	Vernal Keratoconjunctivitis	1
4	Recruiting	Treatment	Vitiligo	1
4	Terminated	Prevention	Chronic Hepatitis C Infection / Transplantation, Liver	1
4	Terminated	Prevention	Impaired Renal Function	1
4	Terminated	Prevention	Skin Cancers / Transplantation, Kidney	1
4	Terminated	Prevention	Transplantation, Renal	1
4	Terminated	Treatment	Diabetes Mellitus (DM)	1
4	Terminated	Treatment	Immunosuppression	1
4	Terminated	Treatment	Kidney Transplant Failure and Rejection	1
4	Terminated	Treatment	Kidney Transplant Recipients	1
4	Terminated	Treatment	Kidney Transplant Rejection	1
4	Terminated	Treatment	Lung and Heart-lung Transplantation	1
4	Terminated	Treatment	Nephritis, Lupus	1
4	Terminated	Treatment	Transplantation, Kidney	2
4	Terminated	Treatment	Transplants and Implants	1
4	Unknown Status	Not Available	New Onset Diabetes After Transplant / Transplantation, Kidney	1
4	Unknown Status	Basic Science	Transplantation, Kidney	1
4	Unknown Status	Prevention	End-stage Renal Failure (ESRF) / Rejection, Transplant	1
4	Unknown Status	Prevention	Immunosuppression / Transplantation, Kidney / Transplantations	2
4	Unknown Status	Prevention	Kidney Transplant Recipients	1
4	Unknown Status	Prevention	Kidney; Complications, Allograft	1
4	Unknown Status	Treatment	De Novo Transplant Disease	2
4	Unknown Status	Treatment	Delayed Graft Function / Slow Graft Function-defined at Creatinine >= 3.0 by Post-op Day 5 Without Requiring Dialysis / Transplant, Kidney	1
4	Unknown Status	Treatment	Dermatitis, Contact / Dermatitis, Occupational	1
4	Unknown Status	Treatment	Hepatitis	1
4	Unknown Status	Treatment	Immunosuppression / Liver Diseases / Transplantation, Liver	1
4	Unknown Status	Treatment	Immunosuppression / Transplant, Kidney	1
4	Unknown Status	Treatment	Infections, Cytomegalovirus	1
4	Unknown Status	Treatment	Kidney Diseases	1
4	Unknown Status	Treatment	Kidney Diseases / Rejection, Transplant	1
4	Unknown Status	Treatment	Pediatric Liver Transplantation	1
4	Unknown Status	Treatment	Transplantation, Kidney	3
4	Unknown Status	Treatment	Vitiligo	2
4	Withdrawn	Not Available	Plasmapheresis / Transplantation, Kidney	1
4	Withdrawn	Treatment	Atopic Dermatitis (AD)	1
4	Withdrawn	Treatment	Kidney Graft Dysfunction	1
4	Withdrawn	Treatment	Living Donor Kidney Transplants Patients	1
Not Available	Active Not Recruiting	Not Available	Glomerulonephritis minimal lesion	1
Not Available	Active Not Recruiting	Not Available	Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis	1
Not Available	Active Not Recruiting	Not Available	Nephritis, Lupus	1
Not Available	Active Not Recruiting	Not Available	Transplant, Kidney / Transplantation, Liver	1
Not Available	Active Not Recruiting	Prevention	Transplantation, Liver	1
Not Available	Active Not Recruiting	Treatment	End Stage Renal Failure With Renal Transplant	1
Not Available	Approved for Marketing	Not Available	Renal Failure	1
Not Available	Available	Not Available	Complete DiGeorge Anomaly / Complete DiGeorge Syndrome / DiGeorge Anomaly / DiGeorge's syndrome	1
Not Available	Completed	Not Available	Healthy Volunteers	4
Not Available	Completed	Not Available	Pediatric Heart Transplant Recipients / Pediatric Heart Transplantation	1
Not Available	Completed	Not Available	Rheumatoid Arthritis	1
Not Available	Completed	Not Available	Transplantation, Liver	1
Not Available	Completed	Not Available	Transplantation, Renal	2
Not Available	Completed	Not Available	The Maintenance Phase After Kidney Transplantation	1
Not Available	Completed	Prevention	Absence; Kidney	1
Not Available	Completed	Prevention	Early Allograft Dysfunction / Hyperfibrinolysis / Ischemic Reperfusion Injury / Transplantation, Liver	1
Not Available	Completed	Screening	Renal Failure, Chronic	1
Not Available	Completed	Screening	Transplantation, Kidney	1
Not Available	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
Not Available	Completed	Treatment	Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Myelodysplastic Syndrome With Isolated Del(5q) / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	1
Not Available	Completed	Treatment	Chronic Allograft Nephropathy (CAN) / Transplantation, Kidney	1
Not Available	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
Not Available	Completed	Treatment	Effects of Immunosuppressant Therapy / Evidence of Liver Transplantation	1
Not Available	Completed	Treatment	Graft Versus Host Disease (GVHD) / Mucositis	1
Not Available	Completed	Treatment	High Model for End-Stage Liver Disease (MELD) Score	1
Not Available	Completed	Treatment	Idiopathic Membranous Nephropathy	1
Not Available	Completed	Treatment	Immunosuppression	1
Not Available	Completed	Treatment	Living Donors / Transplantation, Kidney	1
Not Available	Completed	Treatment	Moderate to Severe Atopic Dermatitis	1
Not Available	Completed	Treatment	Paraneoplastic Syndromes	1
Not Available	Completed	Treatment	Psoriasis Vulgaris	1
Not Available	Completed	Treatment	Transplant, Kidney	1
Not Available	Completed	Treatment	Transplantation, Kidney	2
Not Available	No Longer Available	Not Available	Diabetes, Diabetes Mellitus Type 1	2
Not Available	No Longer Available	Not Available	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous Conditions / Secondary Myelofibrosis	1
Not Available	Not Yet Recruiting	Not Available	Acute Rejection of Renal Transplant / Biopsy Proven Acute Rejection (BPAR) / Bone Diseases / Cardiovascular Risk Factors / Graft Failure / HLA Antibody Production / Infection NOS / Mortality / Non-HLA Antibody Production / Post Transplant Diabetes Mellitus / Quality of Life	1
Not Available	Not Yet Recruiting	Treatment	Heart Transplantation	1
Not Available	Recruiting	Not Available	Biliary Concentration of Tacrolimus	1
Not Available	Recruiting	Not Available	Kidney; Complications, Allograft / Transplantation Infection	1
Not Available	Recruiting	Not Available	Transplantation, Kidney	2
Not Available	Recruiting	Prevention	Immunosuppression / Renal Failure	1
Not Available	Recruiting	Supportive Care	Primary Myelofibrosis / Secondary Myelofibrosis	1
Not Available	Recruiting	Treatment	Acute Graft Rejection / Diabetes	1
Not Available	Recruiting	Treatment	Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia	1
Not Available	Recruiting	Treatment	Agnogenic Myeloid Metaplasia / All / Amyloidosis / Bone Marrow Failure Syndromes / Chronic Myelocytic Leukemia / Haemoglobinopathies congenital / HL / Leukemia Acute Myeloid Leukemia (AML) / Multiple Myeloma (MM) / NHL / Smith-Magenis Syndrome	1
Not Available	Recruiting	Treatment	Allografts / Transplantation, Lung	1
Not Available	Recruiting	Treatment	Disorder Related to Renal Transplantation / Effects of Immunosuppressant Therapy	1
Not Available	Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Hematopoietic/Lymphoid Cancer	1
Not Available	Recruiting	Treatment	Immunosuppression	1
Not Available	Recruiting	Treatment	Liver Transplantation, Child	1
Not Available	Recruiting	Treatment	Malignancies, Hematologic	1
Not Available	Recruiting	Treatment	Malignant Lymphomas	1
Not Available	Recruiting	Treatment	Ocular Penetration of Topical Tacrolimus	1
Not Available	Recruiting	Treatment	Renal Transplanted Recipients	1
Not Available	Recruiting	Treatment	Transplantation, Kidney	1
Not Available	Terminated	Not Available	Dried Blood Spot / Transplant Patients / Validation	1
Not Available	Terminated	Treatment	Oral Lichen Planus	1
Not Available	Terminated	Treatment	Polycystic Liver Disease (PLD)	1
Not Available	Unknown Status	Not Available	Idiopathic Membranous Nephropathy	1
Not Available	Unknown Status	Treatment	Blood and Marrow Transplant (BMT) / Graft Versus Host Disease (GVHD)	1
Not Available	Unknown Status	Treatment	Calcineurin Inhibitor Toxicity / Chronic Allograft Injury	1
Not Available	Unknown Status	Treatment	Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Renal Cancers	1
Not Available	Unknown Status	Treatment	Transplantation, Renal	1
Not Available	Unknown Status	Treatment	MicroRNA Profiles	1
Not Available	Withdrawn	Treatment	Glomerulosclerosis, Focal Segmental	1